[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 139
6. Kang SK, Park JB, Cha SH: Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev; 2006 Jun;15(3):423-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multipotent, dedifferentiated cancer stem-like cells from brain gliomas.
  • In modern cancer biology, external factors and niches can act on differentiated tissue cells to cause cancer by inducing dedifferentiation of mature adult cells.
  • Recently, we discovered that dedifferentiation of glioma cancer cells alters the expression of mature and neural stem cell (NSC)-related genes, in that cancer cells adjust to the serum-deprived environment and cell-to-cell interaction by down-regulating genes associated with neural mature markers and up-regulating genes that are primitive NSC markers.
  • After grafting to severe combined immunodeficient (SCID) mouse brains, dedifferentiated cancer stem cells migrated and continued active proliferation for more than 4 weeks.
  • We also performed microarray analysis and characterized the gene expression patterns in control cancer cells with dedifferentiated cancer stem-like cells.
  • In this report, we propose that the dedifferentiation process of brain tumor and normal tissue may contribute to the malignancy and aggressiveness of the brain cancer.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Cell Differentiation. Glioma / pathology. Multipotent Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. DNA, Complementary / genetics. Drug Resistance. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes / genetics. Humans. Mice. Mice, SCID. Neoplasm Metastasis. Neurons / cytology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Brain Stem Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Stem Cells Dev. 2006 Oct;15(5):749
  • (PMID = 16846378.001).
  • [ISSN] 1547-3287
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger
  •  go-up   go-down


7. Huang AP, Chen JS, Yang CC, Wang KC, Yang SH, Lai DM, Tu YK: Brain stem cavernous malformations. J Clin Neurosci; 2010 Jan;17(1):74-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain stem cavernous malformations.
  • We retrospectively reviewed the clinical experience of 30 patients with brain stem cavernous malformations (BSCM) treated operatively and non-operatively at our hospital between 1983 and 2005 to elucidate the natural history of BSCM and the factors that affect surgical outcome.
  • [MeSH-major] Brain Stem / pathology. Brain Stem / surgery. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / pathology. Hemangioma, Cavernous, Central Nervous System / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Stem Infarctions / etiology. Brain Stem Infarctions / physiopathology. Brain Stem Infarctions / prevention & control. Cerebral Arteries / abnormalities. Cerebral Arteries / pathology. Cerebral Arteries / surgery. Cerebral Veins / abnormalities. Cerebral Veins / pathology. Cerebral Veins / surgery. Child. Female. Humans. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / physiopathology. Intracranial Hemorrhages / prevention & control. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Neurosurgical Procedures / statistics & numerical data. Outcome Assessment (Health Care). Postoperative Hemorrhage / epidemiology. Postoperative Hemorrhage / prevention & control. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20005720.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


8. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC: Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia; 2009 Apr 1;57(5):510-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
  • The capacity of adult human glial progenitor cells (AGPs), to proliferate and undergo multipotent differentiation, positions them as ideal candidate cells of origin for human gliomas.
  • To investigate this potential role we identified AGPs as mitotically active Olig2 cells in nonneoplastic adult human brain and gliomas.
  • Extrapolating from a mean Olig2/Mib-1 labeling index (LI) of 52% and total cell number of 100 billion, we estimated the overall prevalence of mitotic Olig2 AGPs in nonneoplastic human brain parenchyma at 10 million.
  • The novel framework provided by this quantitative and comparative analysis supports future studies to examine the histogenetic role of Olig2 AGPs in adult gliomas, their potential contribution to the tumor stroma and the molecular role of Olig2 in glioma pathogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837053.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; United States / NINDS NIH HHS / NS / T32 NS007144-25; United States / NINDS NIH HHS / NS / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS 0007144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MIB-1 antibody; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  • [Other-IDs] NLM/ NIHMS77469; NLM/ PMC4415884
  •  go-up   go-down


9. Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R: A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol; 2005 Jan;71(2):181-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.
  • PURPOSE: To determine the maximum tolerated dose (MTD) of carboplatin with autologous hematopoietic stem-cell rescue, in children with poor-prognosis brain tumors.
  • PATIENTS AND METHODS: A previously determined dose of cyclophosphamide with stem-cell rescue was used as a first course.
  • In a second course, carboplatin was given for 3 days with stem-cell rescue to 20 children.
  • Toxicity and tumor response were recorded.
  • The median duration of tumor response was 10 months (range: 1.5-87 months) with two children disease free at 66 and 87 months.
  • CONCLUSION: The MTD of carboplatin with stem-cell rescue is 700 mg/m2/day for 3 days.
  • Sequential stem-cell supported cyclophosphamide and carboplatin was tolerable in children with brain tumors and produced responses in PNETs and Germinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Drug Resistance, Neoplasm. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 15;57(2):222-5 [3510700.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):67-73 [9525840.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Bone Marrow Transplant. 1992 Nov;10 (5):457-62 [1464010.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1693-7 [6367971.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Oncologist. 1996;1(6):381-393 [10388020.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;9(3):140-7 [6761010.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):787-94 [12942106.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Cancer Treat Rep. 1984 Sep;68(9):1103-14 [6383605.001]
  • [Cites] J Clin Oncol. 1989 May;7(5):651-61 [2651580.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2426-34 [9667260.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):459-63 [3546620.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1056-68 [8584145.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):520-8 [1548516.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3183-5 [12860965.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5432-8 [6386150.001]
  • [Cites] Cancer Res. 1983 Sep;43(9):4470-3 [6347373.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):69-74 [8817417.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3258-65 [9336363.001]
  • (PMID = 15690136.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Michor F: Mathematical models of cancer stem cells. J Clin Oncol; 2008 Jun 10;26(17):2854-61
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mathematical models of cancer stem cells.
  • Human cancers are thought to be sustained in their growth by a pathologic counterpart of normal adult stem cells: cancer stem cells.
  • This concept was first developed in human myeloid leukemias and is today being extended to solid tumors such as breast and brain cancers.
  • A quantitative understanding of cancer stem cells requires a mathematical framework to describe the dynamics of cancer initiation and progression, the response to treatment, and the evolution of resistance.
  • In this review, I use chronic myeloid leukemia as an example to discuss how mathematical and computational techniques have been used to gain insights into the biology of cancer stem cells.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Models, Biological. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Benzamides. Cell Differentiation. Cell Proliferation. Drug Resistance, Neoplasm. Gene Expression Regulation, Leukemic. Humans. Imatinib Mesylate. Mutation. Patient Selection. Piperazines / pharmacology. Piperazines / therapeutic use. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. Time Factors

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18539964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 65
  •  go-up   go-down


11. Khil'ko VA, Khachatrian VA, Shuleshov NV, Zhabina RM: [Combined treatment of brain stem tumors]. Vestn Khir Im I I Grek; 2005;164(4):11-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment of brain stem tumors].
  • During the two recent decades the introduction of new technologies to neurosurgery resulted in certain progress in diagnosis and combined treatment of brain stem tumors which still remain the most complex problems of neurooncology.
  • Using the present-day diagnostic complex including a thorough dynamic neurological examination, neurophysiological investigations, and visualization methods allowed not only to detect the primary forms of brain stem tumors and their sizes but also to reveal the topographoanatomical interrelationships with the stem structures that allowed to determine the chances of surgical, combined treatment or the radiation and chemotherapy treatment only.
  • The article gives an analysis and the clinical course of the diagnosis and combined treatment of 333 children and adult patients with primary, secondary and peri-trunkal tumors of the brain stem.
  • [MeSH-major] Brain Stem Neoplasms / surgery
  • [MeSH-minor] Adolescent. Algorithms. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Neoplasm Invasiveness. Neoplasm Staging. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755729.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


12. Park HJ, Kim JK, Jeon HM, Oh SY, Kim SH, Nam DH, Kim H: The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. Mol Cells; 2010 Nov;30(5):403-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells.
  • A growing body of evidence indicates that deregulation of stem cell fate determinants is a hallmark of many types of malignancies.
  • The neural stem cell fate determinant TLX plays a pivotal role in neurogenesis in the adult brain by maintaining neural stem cells.
  • Here, we report a tumorigenic role of TLX in brain tumor initiation and progression.
  • Increased TLX expression was observed in a number of glioma cells and glioma stem cells, and correlated with poor survival of patients with gliomas.
  • Ectopic expression of TLX in the U87MG glioma cell line and Ink4a/Arf-deficient mouse astrocytes (Ink4a/Arf(-/-) astrocytes) induced cell proliferation with a concomitant increase in cyclin D expression, and accelerated foci formation in soft agar and tumor formation in in vivo transplantation assays.
  • Furthermore, overexpression of TLX in Ink4a/Arf(-/-) astrocytes inhibited cell migration and invasion and promoted neurosphere formation and Nestin expression, which are hallmark characteristics of glioma stem cells, under stem cell culture conditions.
  • Our results indicate that TLX is involved in glioma stem cell genesis and represents a potential therapeutic target for this type of malignancy.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioma / pathology. Neoplastic Stem Cells / pathology. Neural Stem Cells / pathology. Receptors, Cytoplasmic and Nuclear / physiology
  • [MeSH-minor] Adult. Animals. Astrocytes / metabolism. Astrocytes / pathology. Astrocytoma / genetics. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Central Nervous System Neoplasms. Cyclin D / genetics. Humans. Intermediate Filament Proteins / genetics. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Nerve Tissue Proteins / genetics. Nestin. Neurogenesis. Prognosis. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mol Cells. 2011 Feb ;31(2):199. Park, Myung-Jin [removed]; Soeda, Akio [removed]
  • (PMID = 20814749.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / NR2E1 protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


13. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, Javerzat S, Hagedorn M, Carrabba G, Lucini V, Gaini SM, Bresolin N, Bello L, Bikfalvi A, Torrente Y: Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res; 2007 Apr 1;67(7):3054-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
  • New experimental approaches have shown tumor regression after the grafting of neural stem cells and human mesenchymal stem cells into experimental intracranial gliomas of adult rodents.
  • In the present study, we evaluated the tumor targeting and antitumor activity of human skin-derived stem cells (hSDSCs) in human brain tumor models.
  • The hSDSCs exhibit tumor targeting characteristics in vivo when injected into the controlateral hemisphere or into the tail vein of mice.
  • When implanted directly into glioblastomas, hSDSCs distributed themselves extensively throughout the tumor mass, reduced tumor vessel density, and decreased angiogenic sprouts.
  • In addition, transplanted hSDSCs differentiate into pericyte cell and release high amounts of human transforming growth factor-beta1 with low expression of vascular endothelial growth factor, which may contribute to the decreased tumor cell invasion and number of tumor vessels.
  • In long-term experiments, the hSDSCs were also able to significantly inhibit tumor growth and to prolong animal survival.
  • Similar behavior was seen when hSDSCs were implanted into two different tumor models, the chicken embryo experimental glioma model and the transgenic Tyrp1-Tag mice.
  • Taken together, these data validate the use of hSDSCs for targeting human brain tumors.
  • [MeSH-major] Brain Neoplasms / blood supply. Brain Neoplasms / therapy. Glioblastoma / blood supply. Glioblastoma / therapy. Skin / cytology. Stem Cell Transplantation. Stem Cells / physiology
  • [MeSH-minor] Animals. Cell Growth Processes / physiology. Cell Line, Tumor. Chick Embryo. Chorioallantoic Membrane / blood supply. Humans. Mice. Mice, Nude. Mice, Transgenic. Neoplasm Invasiveness. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / therapy. Transforming Growth Factor beta1 / biosynthesis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409412.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


1
Advertisement
4. Saldanha-Araujo F, Haddad R, Zanette DL, De Araujo AG, Orellana MD, Covas DT, Zago MA, Panepucci RA: Cancer/Testis antigen expression on mesenchymal stem cells isolated from different tissues. Anticancer Res; 2010 Dec;30(12):5023-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer/Testis antigen expression on mesenchymal stem cells isolated from different tissues.
  • BACKGROUND/AIMS: The expression of cancer/testis antigens (CTAs) on additional normal tissues or stem cells may restrict their use as cancer targets.
  • MATERIALS AND METHODS: mRNA of pericytes, fibroblasts and mesenchymal stem cells (MSCs) derived from adult and fetal tissues, human umbilical vein endothelial cells, MSC-derived adipocytes, selected normal tissues and control cancer cell lines (CLs) were extracted and quantitative polymerase chain reaction was performed for MAGED1, PRAME, CTAG1B, MAGEA3 and MAGEA4.
  • CTAG1B was expressed at levels comparable to control CLs on MSCs derived from arterial, fetal skin, adipose tissue and saphenous vein, heart, brain and skin tissues.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Mesenchymal Stromal Cells / immunology
  • [MeSH-minor] Fibroblasts / immunology. Humans. Immunophenotyping. Melanoma-Specific Antigens. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Pericytes / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187485.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / MAGEA4 protein, human; 0 / MAGED1 protein, human; 0 / Melanoma-Specific Antigens; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / PRAME protein, human
  •  go-up   go-down


15. Liu Q, Liu R, Kashyap MV, Agarwal R, Shi X, Wang CC, Yang SH: Brainstem glioma progression in juvenile and adult rats. J Neurosurg; 2008 Nov;109(5):849-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem glioma progression in juvenile and adult rats.
  • OBJECT: Brainstem gliomas are common in children and have the worst prognosis of any brain tumor in this age group.
  • On the other hand, brainstem gliomas are rare in adults, and the authors of some clinical studies have suggested that this lesion behaves differently in adults than in children.
  • In the present study, the authors test an orthotopic C6 brainstem glioma model in juvenile and adult rats, and investigate the biological behavior of this lesion in the 2 age groups.
  • METHODS: The C6 glioma cells were stereotactically implanted into the pons of juvenile or adult male rats.
  • Tumor proliferation and the number of apoptotic cells in brainstem gliomas of young and adult rats were determined by immunohistochemical staining with Ki 67 and terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate-mediated nick-end labeling assay.
  • RESULTS: Striking differences in the onset of neurological signs, duration of symptoms, survival time, tumor growth pattern, tumor proliferation, and number of apoptotic cells were found between the gliomas in the 2 groups of rats.
  • The lesions were relatively focal in adult rats but more diffuse in young rats.
  • Furthermore, brainstem gliomas in adult rats were less proliferative and had more apoptotic cells than those in young rats.
  • CONCLUSIONS: The authors found that the C6 brainstem glioma model in young and adult rats closely imitates the course of brainstem glioma in humans both in neurological findings and histopathological characteristics.
  • Their findings also suggest that the different growth pattern and invasiveness of these lesions in children compared with that in adults could be due to different cellular environments in the 2 age groups, and warrants further investigation into the difference in the host response to brainstem gliomas in children and adults.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Age Factors. Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation. Disease Models, Animal. Disease Progression. Kaplan-Meier Estimate. Male. Neoplasm Transplantation / pathology. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1985;76(1-2):12-7 [4003123.001]
  • [Cites] Oncologist. 2004;9(2):197-206 [15047924.001]
  • [Cites] J Neurosurg. 1987 Oct;67(4):483-7 [3309202.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):309-17 [3221258.001]
  • [Cites] Neurosurg Clin N Am. 1990 Jan;1(1):111-21 [2135963.001]
  • [Cites] J Neurotrauma. 1994 Apr;11(2):187-96 [7932797.001]
  • [Cites] J Neurooncol. 1998 Jan;36(1):91-102 [9525831.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):95-101 [10022534.001]
  • [Cites] Arch Dis Child. 1999 Jun;80(6):558-64 [10332008.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):1064-9 [10491535.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Feb;27(1):7-12 [15782484.001]
  • [Cites] Childs Nerv Syst. 2005 May;21(5):399-403 [15702357.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E11 [16048287.001]
  • [Cites] J Neurosci Res. 2005 Aug 1;81(3):447-55 [15959903.001]
  • [Cites] Br J Neurosurg. 2005 Apr;19(2):128-36 [16120515.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):253-66 [16195805.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] J Clin Neurosci. 2006 May;13(4):431-7 [16678721.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):546-53 [16734735.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1127-35 [16568342.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):281-7 [16598416.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] J Neurooncol. 2000;46(3):193-203 [10902851.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):993-9; discussion 999-1000 [11014444.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):616-24; discussion 624-5 [11270553.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):206-14 [11359114.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]
  • [Cites] Vet Pathol. 2002 May;39(3):293-9 [12014493.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] Childs Nerv Syst. 2004 Mar;20(3):143-53 [14669023.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):11-5 [3941334.001]
  • (PMID = 18976074.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS054651; United States / NINDS NIH HHS / NS / R01 NS054651-01A2; United States / NINDS NIH HHS / NS / R01 NS054687; United States / NINDS NIH HHS / NS / R01 NS054687-01A2
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS75237; NLM/ PMC2693119
  •  go-up   go-down


16. Ehtesham M, Stevenson CB, Thompson RC: Stem cell therapies for malignant glioma. Neurosurg Focus; 2005 Sep 15;19(3):E5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell therapies for malignant glioma.
  • The prognosis for patients with malignant glioma, which is the most common primary intracranial neoplasm, remains dismal despite significant progress in neurooncological therapies and technology.
  • Malignant glial cells often disseminate throughout the brain, making it exceedingly difficult to target and treat all intracranial neoplastic foci, with the result that tumor recurrence is inevitable despite aggressive surgery and adjuvant radiotherapy and/or chemotherapy.
  • The use of neural stem cells (NSCs) as delivery vehicles for tumor-toxic molecules represents the first experimental strategy aimed specifically at targeting disseminated tumor pockets.
  • Investigators have demonstrated that NSCs possess robust tropism for infiltrating tumor cells, and that they can be used to deliver therapeutic agents directly to tumor satellites, with significant therapeutic benefit.
  • With the aim of developing these findings into a clinically viable technology that would not be hindered by ethical and tissue rejection-related concerns, the use of adult tissue-derived stem cells has recently been explored.
  • These technologies represent important progress in the development of a treatment strategy that can specifically target disseminated neoplastic pockets within the brain.
  • Key among these are an inadequate understanding of the specific tropic mechanisms that govern NSC migration toward invasive tumor, and the need to refine the processes used to generate tumor-tropic stem cells from adult tissues so that this can be accomplished in a clinically practicable fashion.
  • Despite these limitations, the use of stem cell therapies for brain tumors holds significant promise and may emerge as an important therapeutic modality for patients with malignant glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Stem Cell Transplantation / methods. Stem Cells / physiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190604.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


17. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Recent advances have led to the identification of specific oncogenic products that are implicated in the malignant transformation of adult stem/progenitor cells into leukemic or tumorigenic and migrating cancer stem/progenitor cells during cancer progression.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


18. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A: Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol; 2007 Aug;4(8):491-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.
  • He received consolidation therapy 3 months later with a matched-unrelated-donor stem-cell transplant.
  • The disease relapsed in the bone marrow (BM) 9 months after the initial stem-cell transplant, and was successfully treated by repeat transplant from the same donor.
  • INVESTIGATIONS: Physical examination, complete blood count, BM biopsy, flow cytometry, cytogenetic analysis, chimera study, tongue biopsy, abdominal-wall biopsy, cytology and immunohistochemistry, CT scan of the chest, abdomen and pelvis, MRI of the brain, and cerebrospinal fluid analysis.
  • DIAGNOSIS: Isolated extramedullary relapse of acute myeloid leukemia after stem-cell transplant.
  • A matched-unrelated-donor stem-cell transplant for consolidation and donor-lymphocyte infusions were performed, followed by repeat unrelated-donor transplant for leukemia relapse in the marrow, radiation therapy and gemtuzumab ozogamicin for multiple sites of extramedullary leukemia relapse.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657254.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


19. Farnie G, Clarke RB: Mammary stem cells and breast cancer--role of Notch signalling. Stem Cell Rev; 2007 Jun;3(2):169-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary stem cells and breast cancer--role of Notch signalling.
  • Adult stem cells are found in numerous tissues of the body and play a role in tissue development, replacement and repair.
  • Evidence shows that breast stem cells are multipotent and can self renew, which are key characteristics of stem cells, and a single cell enriched with cell surface markers has the ability to grow a fully functional mammary gland in vivo.
  • Many groups have extrapolated the cancer stem cell hypothesis from the haematopoietic system to solid cancers, where using in vitro culture techniques and in vivo transplant models have established evidence of cancer stem cells in colon, pancreas, prostate, brain and breast cancers.
  • In the report we describe the evidence for breast cancer stem cells; studies consistently show that stem cell like and breast cancer initiating populations can be enriched using cell surface makers CD44+/CD24- and have upregulated genes which include Notch.
  • A gamma-secretase inhibitor, DAPT, which inhibits all four Notch receptors and a Notch 4 neutralising antibody were shown to reduce DCIS mammosphere formation, indicating that Notch signalling and other stem cell self-renewal pathways may represent novel therapeutic targets to prevent recurrence of pre-invasive and invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Mammary Glands, Human / metabolism. Multipotent Stem Cells / metabolism. Neoplastic Stem Cells / metabolism. Receptor, Notch1 / metabolism
  • [MeSH-minor] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Amyloid Precursor Protein Secretases / metabolism. Animals. Antigens, CD24 / metabolism. Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Dipeptides / pharmacology. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic. Humans. Mammary Glands, Animal / metabolism. Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Mammary Neoplasms, Experimental / prevention & control. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Transplantation. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stem Cells. 2007 Mar;25(3):807-15 [17158237.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Cell Growth Differ. 1995 May;6(5):563-77 [7544153.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):616-27 [17440163.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3311-4 [12610207.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Nat Med. 1997 Dec;3(12 ):1337-45 [9396603.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Genes Dev. 1992 Mar;6(3):345-55 [1372276.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):402-4 [8542598.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14 ):6207-19 [16024622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):215-21 [15492044.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Development. 1997 Mar;124(6):1139-48 [9102301.001]
  • [Cites] Dev Biol. 1998 Apr 15;196(2):204-17 [9576833.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):409-17 [16049327.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6 [17185413.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):444-60 [15212947.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10946-51 [16322242.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98 (24):1777-85 [17179479.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3505-13 [15060169.001]
  • [Cites] Dev Biol. 2005 Jan 15;277(2):443-56 [15617686.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:59-72 [14521516.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):341-7 [15288259.001]
  • [Cites] J Embryol Exp Morphol. 1986 Jul;96:229-43 [3805986.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Development. 2004 Mar;131(5):965-73 [14973298.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Sep;61(1):53-60 [4301594.001]
  • [Cites] Cell. 1997 Feb 7;88(3):287-98 [9039255.001]
  • [Cites] Genes Dev. 2003 May 15;17 (10 ):1253-70 [12756227.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1775-85 [8620493.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 [15020770.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):552-60 [15580303.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Development. 2003 Aug;130(15):3459-68 [12810593.001]
  • [Cites] Nature. 1967 Jan 14;213(5072):193-4 [6030584.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8530-7 [16166334.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):75-86 [15886888.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1517-25 [16452208.001]
  • [Cites] J Cell Biol. 2007 Feb 12;176(4):445-58 [17296795.001]
  • (PMID = 17873349.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD24 protein, human; 0 / CD44 protein, human; 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Number-of-references] 58
  •  go-up   go-down


20. Gajera CR, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, Yoshikawa K, Bachmann S, Christensen EI, Götz M, Kempermann G, Peterson AS, Willnow TE, Hammes A: LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci; 2010 Jun 1;123(Pt 11):1922-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche.
  • The microenvironment of growth factors in the subependymal zone (SEZ) of the adult brain provides the instructive milieu for neurogenesis to proceed in this germinal niche.
  • We demonstrate that LRP2, a clearance receptor for BMP4 is specifically expressed in ependymal cells of the lateral ventricles in the adult brain.
  • Intriguingly, expression is restricted to the ependyma that faces the stem cell niche.
  • Expression is not seen in ependyma elsewhere in the lateral ventricles or in the dentate gyrus, the second major neurogenic zone of the adult brain.
  • We further show that lack of LRP2 expression in adult mice results in impaired proliferation of neural precursor cells in the SEZ resulting in decreased numbers of neuroblasts reaching the olfactory bulb.
  • Reduced neurogenesis coincides with increased BMP4 expression and enhanced activation of downstream mediators phospho-SMAD1/5/8 and ID3 in the stem cell niche.
  • Our findings suggest a novel mechanism whereby LRP2-mediated catabolism of BMP4 in the ependyma modulates the microenvironment of the SEZ and enables adult neurogenesis to proceed.
  • [MeSH-major] Adult Stem Cells / metabolism. Bone Morphogenetic Protein 4 / metabolism. Ependyma / metabolism. Low Density Lipoprotein Receptor-Related Protein-2 / metabolism. Stem Cell Niche / metabolism
  • [MeSH-minor] Animals. Cell Proliferation. Cells, Cultured. Gene Expression Regulation. Immunohistochemistry. Inhibitor of Differentiation Proteins / metabolism. Mice. Mice, Mutant Strains. Neoplasm Proteins / metabolism. Neurogenesis / genetics. Olfactory Receptor Neurons / cytology. Sequence Deletion / genetics. Signal Transduction. Smad Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460439.001).
  • [ISSN] 1477-9137
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 4; 0 / Inhibitor of Differentiation Proteins; 0 / Low Density Lipoprotein Receptor-Related Protein-2; 0 / Lrp2 protein, mouse; 0 / Neoplasm Proteins; 0 / Smad Proteins; 147785-34-0 / ID3 protein, human
  •  go-up   go-down


21. Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, Norton J, Birse CE, He T, Ruben SM, Moore PA: Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer; 2010 Apr 13;102(8):1265-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.
  • BACKGROUND: Despite earlier studies demonstrating in vitro propagation of solid tumour cancer stem cells (CSCs) as non-adherent tumour spheres, it remains controversial as to whether CSCs can be maintained in vitro.
  • [MeSH-major] Antigens, CD / metabolism. Colonic Neoplasms / pathology. Glycoproteins / metabolism. Neoplastic Stem Cells. Peptides / metabolism. Spheroids, Cellular. Tumor Cells, Cultured
  • [MeSH-minor] ATP-Binding Cassette Transporters / genetics. Adult. Aged. Aged, 80 and over. Animals. Cell Differentiation. Drug Resistance, Neoplasm. Female. Humans. Male. Mass Spectrometry. Membrane Proteins / analysis. Mice. Mice, Nude. Mice, SCID. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Transplantation. Proteomics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):657-67 [11522750.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1565-77 [12404231.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Dig Dis Sci. 2003 Aug;48(8):1523-9 [12924647.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Lett. 2004 Apr 15;207(1):109-15 [15050740.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85 [17179479.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):345-9 [18202660.001]
  • [Cites] World J Gastroenterol. 2008 Feb 14;14(6):925-30 [18240351.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2091-6 [17934519.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] PLoS One. 2008;3(4):e1936 [18398462.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nat Biotechnol. 2009 Jan;27(1):44-6 [19131997.001]
  • [Cites] Mol Cell Proteomics. 2009 Apr;8(4):624-38 [19036722.001]
  • [Cites] Anal Biochem. 2009 Oct 15;393(2):155-62 [19538932.001]
  • [Cites] Cell. 2009 Aug 21;138(4):645-59 [19682730.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Adv Carbohydr Chem. 1956;48(11):1-41 [13469627.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8809-17 [16204051.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Am J Pathol. 2006 Jun;168(6):1879-88 [16723703.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4403-11 [10969785.001]
  • (PMID = 20332776.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2855999
  •  go-up   go-down


22. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol; 2006 Jul;19(7):974-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells.
  • Some brain tumors such as anaplastic ependymoma, some medulloblastomas, glioblastoma, pineal germinoma, craniopharyngioma, choroid plexus papilloma, choroid plexus carcinoma, and meningioma showed positive immunoreactivity with D2-40.
  • Therefore, D2-40 antibody is considered a useful marker for research on developing brain and diagnosis of brain tumors, differentiation between choroid plexus carcinoma and metastatic carcinoma.
  • In addition, on cultured human neural cells, D2-40 immunoreactivity was found in nestin-positive neural stem/progenitor cells and neuronal lineage cells.
  • As D2-40 antibody recognizes cell surface antigen M2A, it might be a candidate cell surface marker for isolation of human neural stem cells/neuronal lineage cells in the fluorescence-activated cell sorting technique.
  • [MeSH-major] Antibodies, Monoclonal. Antigens, Neoplasm / analysis. Brain Neoplasms / immunology. Cerebellum / immunology. Telencephalon / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation. Cells, Cultured. Child, Preschool. Fetus / immunology. Gestational Age. Humans. Immunohistochemistry. Infant. Middle Aged. Neurons / cytology. Neurons / immunology. Prosencephalon / cytology. Stem Cells / cytology. Stem Cells / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648867.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


23. Dai KY, Chan SH, Chang AY: Heme oxygenase-1 plays a pro-life role in experimental brain stem death via nitric oxide synthase I/protein kinase G signaling at rostral ventrolateral medulla. J Biomed Sci; 2010;17:72
Hazardous Substances Data Bank. MEVINPHOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heme oxygenase-1 plays a pro-life role in experimental brain stem death via nitric oxide synthase I/protein kinase G signaling at rostral ventrolateral medulla.
  • BACKGROUND: Despite its clinical importance, a dearth of information exists on the cellular and molecular mechanisms that underpin brain stem death.
  • A suitable neural substrate for mechanistic delineation on brain stem death resides in the rostral ventrolateral medulla (RVLM) because it is the origin of a life-and-death signal that sequentially increases (pro-life) and decreases (pro-death) to reflect the advancing central cardiovascular regulatory dysfunction during the progression towards brain stem death in critically ill patients.
  • The present study evaluated the hypothesis that heme oxygnase-1 (HO-1) may play a pro-life role as an interposing signal between hypoxia-inducible factor-1 (HIF-1) and nitric oxide synthase I (NOS I)/protein kinase G (PKG) cascade in RVLM, which sustains central cardiovascular regulatory functions during brain stem death.
  • METHODS: We performed cardiovascular, pharmacological, biochemical and confocal microscopy experiments in conjunction with an experimental model of brain stem death that employed microinjection of the organophosphate insecticide mevinphos (Mev; 10 nmol) bilaterally into RVLM of adult male Sprague-Dawley rats.
  • RESULTS: Western blot analysis coupled with laser scanning confocal microscopy revealed that augmented HO-1 expression that was confined to the cytoplasm of RVLM neurons occurred preferentially during the pro-life phase of experimental brain stem death and was antagonized by immunoneutralization of HIF-1α or HIF-1β in RVLM.
  • CONCLUSIONS: We conclude that transcriptional upregulation of HO-1 on activation by HIF-1 in RVLM plays a preferential pro-life role by sustaining central cardiovascular regulatory functions during brain stem death via upregulation of NOS I/PKG signaling pathway.
  • [MeSH-major] Brain Death / physiopathology. Heme Oxygenase-1 / metabolism. Insecticides / toxicity. Medulla Oblongata / drug effects. Mevinphos / toxicity. Signal Transduction / physiology
  • [MeSH-minor] Analysis of Variance. Animals. Blotting, Western. Cyclic GMP-Dependent Protein Kinases / metabolism. Fluorescent Antibody Technique. Gene Knockdown Techniques. Male. Microscopy, Confocal. Neoplasm Proteins / metabolism. Nitric Oxide Synthase Type I / metabolism. Oligonucleotides / genetics. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 2):H485-92 [9038971.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5375-81 [9038135.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 1):L212-9 [9486205.001]
  • [Cites] J Neurochem. 1999 Mar;72(3):1187-203 [10037492.001]
  • [Cites] EMBO J. 1999 Apr 1;18(7):1905-14 [10202154.001]
  • [Cites] J Neurol. 1999 Jun;246(6):432-7 [10431766.001]
  • [Cites] Neuropharmacology. 2005 Jan;48(1):161-72 [15617736.001]
  • [Cites] Shock. 2005 Apr;23(4):353-9 [15803059.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):17-23 [15832944.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jun;25(6):297-310 [15957953.001]
  • [Cites] Biochem Cell Biol. 2005 Oct;83(5):597-607 [16234848.001]
  • [Cites] Prog Neurobiol. 2005 Dec;77(6):396-425 [16376477.001]
  • [Cites] Physiol Rev. 2006 Apr;86(2):583-650 [16601269.001]
  • [Cites] J Neurochem. 2006 Aug;98(4):1200-16 [16787408.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4585-600 [17150954.001]
  • [Cites] J Physiol. 2007 Jun 15;581(Pt 3):1293-307 [17395621.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 31;360(3):646-52 [17610843.001]
  • [Cites] Cell. 2007 Oct 19;131(2):309-23 [17956732.001]
  • [Cites] Antioxid Redox Signal. 2007 Dec;9(12):2209-25 [17887916.001]
  • [Cites] Cell. 2007 Nov 2;131(3):584-95 [17981124.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2055-64, 2064.e1-2 [18926825.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5364-74 [19474404.001]
  • [Cites] Shock. 2009 Dec;32(6):651-8 [19333137.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R403-14 [16973934.001]
  • [Cites] Circ Res. 2000 Feb 18;86(3):319-25 [10679484.001]
  • [Cites] Crit Care Med. 2000 Aug;28(8):2805-11 [10966254.001]
  • [Cites] Mol Cells. 2000 Oct 31;10(5):566-74 [11101149.001]
  • [Cites] Shock. 2001 Jan;15(1):35-41 [11198355.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1163-71 [11342580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10996-1002 [11572959.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Nov;281(5):F900-8 [11592948.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2249-55 [12814358.001]
  • [Cites] Neuropharmacology. 2004 Jun;46(8):1184-94 [15111025.001]
  • [Cites] Shock. 2004 Apr;21(4):358-63 [15179137.001]
  • [Cites] J Neurochem. 2004 Jul;90(2):368-78 [15228594.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 5;324(1):394-400 [15465032.001]
  • [Cites] Br Med J. 1976 Nov 13;2(6045):1187-8 [990836.001]
  • [Cites] Br Med J. 1979 Feb 3;1(6159):332 [421104.001]
  • [Cites] JAMA. 1981 Nov 13;246(19):2184-6 [7289009.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Jan 1;286(6358):39 [6401455.001]
  • [Cites] Am J Physiol. 1993 Jun;264(6 Pt 2):H2208-13 [8322952.001]
  • [Cites] J Physiol. 1994 Jan 1;474(1):1-19 [8014887.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):75-80 [7823073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1683-93 [7500013.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Dec;275(3):1568-74 [8531130.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):9-19 [8679227.001]
  • [Cites] Crit Care Med. 1997 Feb;25(2):258-66 [9034261.001]
  • [Cites] Am J Physiol. 1997 Sep;273(3 Pt 2):H1291-8 [9321818.001]
  • (PMID = 20819234.001).
  • [ISSN] 1423-0127
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIG1 protein, human; 0 / Insecticides; 0 / Neoplasm Proteins; 0 / Oligonucleotides; 7786-34-7 / Mevinphos; EC 1.14.13.39 / Nitric Oxide Synthase Type I; EC 1.14.99.3 / Heme Oxygenase-1; EC 2.7.11.12 / Cyclic GMP-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC2941487
  •  go-up   go-down


24. Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer; 2008 Nov;51(5):675-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
  • PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells.
  • CONCLUSION: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] Neuro Oncol. 2003 Oct;5(4):261-7 [14565163.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1199-204 [10098759.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4622-7 [17925558.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):273-8 [16195803.001]
  • [Cites] Expert Rev Neurother. 2006 May;6(5):765-79 [16734524.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2291-7 [17019740.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):285-91 [16598761.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • (PMID = 18623206.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098413-06; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098413-06; None / None / / U10 CA098543-06
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS123029; NLM/ PMC2900925
  •  go-up   go-down


25. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J: Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res; 2008;27:85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
  • AIM: Gliomas represent the most frequent neoplasm of the central nervous system.
  • Unfortunately, surgical cure of it is practically impossible and their clinical course is primarily determined by the biological behaviors of the tumor cells.
  • The aim of this study was to investigate the correlation of the stem cell markers Nestin and CD133 expression with the grading of gliomas, and to evaluate their prognostic value.
  • METHODS: The tissue samples consisted of 56 low- (WHO grade II), 69 high- (WHO grade III, IV) grade gliomas, and 10 normal brain tissues.
  • RESULTS: Immunohistochemical analysis with anti-Nestin and anti-CD133 antibodies revealed dense and spotty staining in the tumor cells and their expression levels became significantly higher as the glioma grade advanced (p < 0.05).
  • A combined detection of Nestin/CD133 co-expression may benefit us in the prediction of aggressive nature of this tumor.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Glioma / metabolism. Glycoproteins / biosynthesis. Intermediate Filament Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Nestin. Peptides. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2387-95 [11489817.001]
  • [Cites] J Physiol Paris. 2002 Jan-Mar;96(1-2):81-90 [11755786.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):228-33 [15102349.001]
  • [Cites] J Neurooncol. 2004 Jun;68(2):113-21 [15218947.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Radiother Oncol. 1991 Feb;20(2):99-110 [1851573.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 [9356465.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):791-804 [15917475.001]
  • [Cites] BMC Cancer. 2006;6:32 [16457706.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):485-92 [16418842.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):272-7 [16538520.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):227-33 [16826367.001]
  • [Cites] Surg Neurol. 2007 Aug;68(2):133-43; discussion 143-4 [17537489.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6970-7 [18056172.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):467-73 [17873113.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • (PMID = 19108713.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Peptides
  • [Other-IDs] NLM/ PMC2633002
  •  go-up   go-down


26. Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Boehmler AM, Wischhusen J, Rieger J, Blümcke I, Weller M, Wick W: Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain; 2005 Sep;128(Pt 9):2200-11
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells.
  • Stem and progenitor cells (PCs) of various lineages have become attractive vehicles to improve therapeutic gene delivery to cancers, notably glioblastoma.
  • Here we report that adult human and murine haematopoietic PCs display a tropism for intracerebral gliomas but not for normal brain tissue in mice.
  • We delineate a CXC chemokine ligand (CXCL) 12-dependent pathway of TGF-beta-induced PC migration that is facilitated by MMP-9-mediated stem cell factor cleavage in vitro.
  • Thus, we define here the molecular mechanism underlying the glioma tropism of the probably most easily accessible PC population suitable for cancer therapy, that is, adult haematopoietic PC.
  • [MeSH-major] Brain Neoplasms / pathology. Chemotaxis. Glioma / pathology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / cytology
  • [MeSH-minor] Adult. Animals. Chemokine CXCL12. Chemokines, CXC / physiology. Humans. Matrix Metalloproteinase 9 / physiology. Mice. Mice, Nude. Neoplasm Transplantation. Stem Cell Factor / physiology. Transforming Growth Factor beta / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947066.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Stem Cell Factor; 0 / Transforming Growth Factor beta; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


27. Nohroudi K, Arnhold S, Berhorn T, Addicks K, Hoehn M, Himmelreich U: In vivo MRI stem cell tracking requires balancing of detection limit and cell viability. Cell Transplant; 2010;19(4):431-41
Hazardous Substances Data Bank. HEMATITE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo MRI stem cell tracking requires balancing of detection limit and cell viability.
  • Cell-based therapy using adult mesenchymal stem cells (MSCs) has already been the subject of clinical trials, but for further development and optimization the distribution and integration of the engrafted cells into host tissues have to be monitored.
  • [MeSH-major] Cell Movement. Contrast Media / analysis. Ferric Compounds / analysis. Magnetic Resonance Imaging. Mesenchymal Stem Cell Transplantation. Metal Nanoparticles / analysis
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Brain Neoplasms / therapy. Cell Survival. Glioma / therapy. Male. Neoplasm Transplantation. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149297.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Ferric Compounds; 1K09F3G675 / ferric oxide
  •  go-up   go-down


28. Capitini CM, Derdak J, Hughes MS, Love CP, Baird K, Mackall CL, Fry TJ: Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol; 2009 Feb;31(2):142-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.
  • Allogeneic stem cell transplantation (SCT) for solid tumors remains under investigation.
  • Of note, the patient developed metastatic disease to 2 unusual sites-the brain and small intestine.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Neoplasm Metastasis / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Humans. Intestinal Neoplasms / secondary. Male. Transplantation, Homologous. Treatment Failure

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Surg Neurol. 1989 Mar;31(3):234-8 [2922669.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):930-9 [15776111.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):31-3 [17222750.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):519-22 [17309187.001]
  • [Cites] Oncologist. 2007 Aug;12(8):1007-18 [17766661.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):142-4 [18266223.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):242-4 [15625381.001]
  • [Cites] Eur J Pediatr Surg. 2003 Aug;13(4):272-5 [13680499.001]
  • [Cites] Pediatr Neurol. 2002 Mar;26(3):219-21 [11955930.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Nov;23(8):530-2 [11878783.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1451-62 [11142486.001]
  • [Cites] J R Coll Surg Edinb. 2001 Dec;46(6):372-4 [11768578.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):158-64 [11836714.001]
  • (PMID = 19194203.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS87241; NLM/ PMC2644462
  •  go-up   go-down


29. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


30. Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez Y Baena R, Gaetani P, Pelicci G, Allavena P: Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer; 2010 Dec;46(18):3383-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1.
  • The most severe form, the glioblastoma multiforme, is characterised by a marked and diffuse infiltration through the normal brain parenchyma.
  • Glioblastoma-derived neurospheres, containing a mixed population of stem and progenitor cells, were positive for both CX3CR1 and for the membrane-bound chemokine, which was further up-regulated and secreted after TNF-IFNγ stimulation.
  • [MeSH-major] Brain Neoplasms / metabolism. Chemokine CX3CL1 / metabolism. Glioblastoma / metabolism. Neoplasm Proteins / metabolism. Neoplastic Stem Cells / metabolism. Receptors, Interleukin-8A / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20728344.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CX3CL1; 0 / Neoplasm Proteins; 0 / Receptors, Interleukin-8A
  •  go-up   go-down


31. Lin T, Islam O, Heese K: ABC transporters, neural stem cells and neurogenesis--a different perspective. Cell Res; 2006 Nov;16(11):857-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporters, neural stem cells and neurogenesis--a different perspective.
  • Stem cells intrigue.
  • They have the ability to divide exponentially, recreate the stem cell compartment, as well as create differentiated cells to generate tissues.
  • Stem cells have the capacity to generate specific tissues or even whole organs like the blood, heart, or bones.
  • A subgroup of stem cells, the neural stem cells (NSCs), is characterized as a self-renewing population that generates neurons and glia of the developing brain.
  • They can be isolated, genetically manipulated and differentiated in vitro and reintroduced into a developing, adult or a pathologically altered central nervous system.
  • Characterization of genes with tightly controlled expression patterns during differentiation represents an approach to understanding the regulation of stem cell commitment.
  • The regulation of stem cell biology by the ATP-binding cassette (ABC) transporters has emerged as an important new field of investigation.
  • As a major focus of stem cell research is in the manipulation of cells to enable differentiation into a targeted cell population; in this review, we discuss recent literatures on ABC transporters and stem cells, and propose an integrated view on the role of the ABC transporters, especially ABCA2, ABCA3, ABCB1 and ABCG2, in NSCs' proliferation, differentiation and regulation, along with comparisons to that in hematopoietic and other stem cells.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Neurons / cytology. Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Proliferation. Gene Expression / genetics. Humans. Models, Biological. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Proteins / physiology. Organic Anion Transporters / genetics. Organic Anion Transporters / metabolism. Organic Anion Transporters / physiology. P-Glycoprotein. P-Glycoproteins

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088897.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / Neoplasm Proteins; 0 / Organic Anion Transporters; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  • [Number-of-references] 181
  •  go-up   go-down


32. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer; 2006 Dec 02;5:67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
  • BACKGROUND: Recently, a small population of cancer stem cells in adult and pediatric brain tumors has been identified.
  • Some evidence has suggested that CD133 is a marker for a subset of leukemia and glioblastoma cancer stem cells.
  • The gene expression and the drug resistance property of CD133 positive cancer stem cells, however, are still unknown.
  • CONCLUSION: Our study for the first time provided evidence that CD133 positive cancer stem cells display strong capability on tumor's resistance to chemotherapy.
  • Future treatment should target this small population of CD133 positive cancer stem cells in tumors to improve the survival of brain tumor patients.

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1881-92 [10557066.001]
  • [Cites] Cancer Treat Rev. 2006 Jun;32(4):261-76 [16698182.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6 [11550138.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3459-74 [12032782.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):397-406 [12142169.001]
  • [Cites] Curr Protein Pept Sci. 2002 Oct;3(5):503-11 [12369998.001]
  • [Cites] Exp Neurol. 2002 Dec;178(2):288-93 [12504887.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Neurochem. 2004 Jan;88(1):212-26 [14675165.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):287-93 [15153341.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7267-73 [15378086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Nature. 1991 Sep 26;353(6342):353-5 [1922340.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4251-6 [8395979.001]
  • [Cites] Biochemistry. 1994 Aug 9;33(31):9045-51 [8049205.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1667-73 [7564507.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1337-45 [9396603.001]
  • [Cites] Mol Pharmacol. 1998 Aug;54(2):334-41 [9687575.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1758-66 [10430080.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3319-27 [15833865.001]
  • [Cites] Nat Neurosci. 2005 Jun;8(6):723-9 [15908947.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1401-9 [10778970.001]
  • (PMID = 17140455.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS048959; United States / NINDS NIH HHS / NS / K23 NS002232; United States / NINDS NIH HHS / NS / 1R21 NS048879; United States / NINDS NIH HHS / NS / R21 NS048879; United States / NINDS NIH HHS / NS / 1R01 NS048959; United States / NINDS NIH HHS / NS / 1K23NS02232
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Glycoproteins; 0 / Peptides; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1697823
  •  go-up   go-down


33. Moviglia GA, Carrizo AG, Varela G, Gaeta CA, Paes de Lima A, Farina P, Molina H: Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):3-13
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme.
  • BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance.
  • Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells.
  • RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation.
  • Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation.
  • A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone.
  • CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction.
  • [MeSH-major] B-Lymphocytes / transplantation. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Glioblastoma / therapy. Hybridomas / transplantation. Neoplastic Stem Cells / transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / transplantation. Lymphocyte Culture Test, Mixed. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063522.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


34. Medhkour A, Chan M: Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature. Surg Neurol; 2005 Jun;63(6):576-82; discussion 582-3
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature.
  • Proper diagnosis via histopathologic and immunochemical staining with close clinical and radiological follow-up is important for the management of this very aggressive tumor.
  • CASE DESCRIPTION: The authors report the clinical features, histopathologic and immunochemical staining characteristics, as well as the radiographic evidence of a case of primary GBM of the conus medullaris with metastases to the whole spinal cord and brain in a 20-year-old man who presented with low back pain and bilateral lower extremity weakness and numbness.
  • Serial magnetic resonance scans, performed after the initial surgery, demonstrated enlargement of the primary GBM in the conus medullaris with metastases to the thoracic and cervical spinal cord as well as to the brain.
  • [MeSH-major] Brain Stem Neoplasms / secondary. Glioblastoma / secondary. Spinal Cord Compression / pathology. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Disease Progression. Fatal Outcome. Glial Fibrillary Acidic Protein / metabolism. Humans. Low Back Pain / etiology. Low Back Pain / pathology. Low Back Pain / physiopathology. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Rare Diseases. Respiratory Insufficiency / etiology. Respiratory Insufficiency / pathology. Respiratory Insufficiency / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936395.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 13
  •  go-up   go-down


35. An JH, Lee SY, Jeon JY, Cho KG, Kim SU, Lee MA: Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res; 2009 Jun;8(6):2873-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gliotropic factors that induce human stem cell migration to malignant tumor.
  • Neural stem cells are mobile, are attracted to regions of brain damage, and can migrate a considerable distance to reach a glioma site.
  • This research is expected to provide clues to the molecular mechanisms underlying the migration of neural stem cells (F3 cell) to glioma sites.
  • These results reveal that this novel molecular approach to the monitoring of glioma may provide clinically relevant information regarding tumor malignancy, and should also prove appropriate for high-throughput clinical screening applications.
  • [MeSH-major] Cell Movement. Glioma / genetics. Glioma / metabolism. Neurons / cytology. Stem Cells / physiology
  • [MeSH-minor] Adult. Aged. Annexin A2 / genetics. Annexin A2 / metabolism. Blotting, Western. Cell Line. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Oligonucleotide Array Sequence Analysis. Proteomics / methods. Reproducibility of Results. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351187.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANXA2 protein, human; 0 / Annexin A2; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins
  •  go-up   go-down


36. Gilheeney SW, Khakoo Y, Souweidane M, Wolden S, Boulad F, Dunkel IJ: Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr Blood Cancer; 2010 Apr;54(4):591-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.
  • Topotecan potentiates the anti-cancer effects of alkylators and crosses the blood-brain barrier.
  • Stem cell rescue was on day 0.
  • Four of the seven patients with no evidence of disease/minimal residual disease status at the time of stem cell rescue are long-term survivors versus 1/3 with measurable disease.
  • Diagnosis and extent of disease prior to stem cell rescue may have an impact on outcome.
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Prognosis. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998470.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


37. Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med; 2007 Sep-Oct;11(5):981-1011
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.
  • Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers.
  • This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant transformation of adult stem/progenitor cells.
  • We describe the critical functions provided by several growth factor cascades, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/beta-catenin signalling pathways that are frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and drug resistance.
  • Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which remain incurable in the clinics.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979879.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA72712; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / P50 CA072712; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 242
  • [Other-IDs] NLM/ PMC4401269
  •  go-up   go-down


38. Bera TK, Saint Fleur A, Ha D, Yamada M, Lee Y, Lee B, Hahn Y, Kaufman DS, Pera M, Pastan I: Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. Stem Cells Dev; 2008 Apr;17(2):325-32
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells.
  • The expression of the POTE gene in normal adult tissues is restricted, but several POTE paralogs are frequently expressed in many cancers including breast, prostate, and lung cancers.
  • We show here that POTE is expressed in several human embryonic stem (ES) cell lines.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447647.001).
  • [ISSN] 1547-3287
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL077923-02; United States / NHLBI NIH HHS / HL / R01 HL077923; United States / NHLBI NIH HHS / HL / R01 HL077923-02; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / POTE-2alpha protein, human; 0 / POTE-2beta protein, human; 0 / POTE-2gamma protein, human; 0 / Protein Isoforms; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


39. Curtis KM, Gomez LA, Rios C, Garbayo E, Raval AP, Perez-Pinzon MA, Schiller PC: EF1alpha and RPL13a represent normalization genes suitable for RT-qPCR analysis of bone marrow derived mesenchymal stem cells. BMC Mol Biol; 2010 Aug 17;11:61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EF1alpha and RPL13a represent normalization genes suitable for RT-qPCR analysis of bone marrow derived mesenchymal stem cells.
  • CONCLUSIONS: In order to make comparisons between heterogeneous MSC populations, as well as adult stem cell like MSC which are used in different laboratories throughout the world, it is important to have a standardized, reproducible set of housekeeping genes for RT-qPCR analysis.

  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3213-8 [10725391.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1604-5 [17046583.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Brain Res. 2002 Oct 18;952(2):153-8 [12376175.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Neurosci. 2003 Jan 15;23(2):384-91 [12533598.001]
  • [Cites] Exp Hematol. 2003 Dec;31(12):1323-30 [14662341.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):2971-81 [15173316.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):481-8 [15474453.001]
  • [Cites] Methods Mol Biol. 1997;72:15-22 [9249734.001]
  • [Cites] Biotechniques. 2005 Jul;39(1):75-85 [16060372.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1608-10 [17046585.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3139-49 [17099777.001]
  • [Cites] Bone. 2007 Feb;40(2):360-73 [17085092.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1743-51 [17062733.001]
  • [Cites] Blood. 2007 May 15;109(10):4245-8 [17264296.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3438-46 [17525288.001]
  • [Cites] Stem Cells. 2007 Nov;25(11):2797-808 [17656644.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):811-26 [17999602.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1826-33 [18209080.001]
  • [Cites] Brain Behav Immun. 2008 May;22(4):442-50 [18061399.001]
  • [Cites] PLoS One. 2008;3(6):e2563 [18575622.001]
  • [Cites] Mol Cell Neurosci. 2008 Oct;39(2):285-90 [18691653.001]
  • [Cites] Nat Rev Immunol. 2008 Sep;8(9):726-36 [19172693.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):497-510 [18598159.001]
  • [Cites] J Cell Physiol. 2009 Jul;220(1):21-9 [19326392.001]
  • [Cites] Transplantation. 2009 May 15;87(9 Suppl):S36-42 [19424002.001]
  • [Cites] Stem Cells. 2009 Mar;27(3):670-81 [19267325.001]
  • [Cites] Mol Ther. 2009 Jun;17(6):939-46 [19337235.001]
  • [Cites] Exp Cell Res. 2009 Sep 10;315(15):2624-36 [19460366.001]
  • [Cites] PLoS One. 2009;4(8):e6792 [19710927.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:135-43 [19796241.001]
  • [Cites] Histochem Cell Biol. 2009 Nov;132(5):547-57 [19711092.001]
  • [Cites] Biomaterials. 2010 Jan;31(3):467-80 [19815272.001]
  • [Cites] Stem Cell Rev. 2009 Dec;5(4):378-86 [20058201.001]
  • [Cites] Haematologica. 2010 Jan;95(1):47-56 [19713224.001]
  • [Cites] Pediatr Surg Int. 2010 Jan;26(1):3-10 [19727766.001]
  • [Cites] Tissue Eng Part A. 2010 Feb;16(2):453-64 [19705961.001]
  • [Cites] J Biomater Appl. 2010 Jul;25(1):39-56 [19726532.001]
  • [Cites] Nat Biotechnol. 2006 Feb;24(2):185-7 [16388305.001]
  • [Cites] Rejuvenation Res. 2006 Spring;9(1):10-9 [16608390.001]
  • [Cites] Bone. 2006 Sep;39(3):513-22 [16616713.001]
  • [Cites] Cytotherapy. 2006;8(4):315-7 [16923606.001]
  • [Cites] Biophys J. 2001 Aug;81(2):685-96 [11463617.001]
  • (PMID = 20716364.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS045676; United States / NINDS NIH HHS / NS / #NS34773; United States / NINDS NIH HHS / NS / NS045676-06; United States / NCRR NIH HHS / RR / #P40RR017447; United States / NINDS NIH HHS / NS / R01 NS045676-06; United States / NINDS NIH HHS / NS / R01 NS034773
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Molecular Chaperones; 0 / Neoplasm Proteins; 0 / Peptide Elongation Factor 1; 0 / RPL13 protein, human; 0 / Ribosomal Proteins; 0 / Ywhaz protein, rat; 103107-01-3 / Fibroblast Growth Factor 2; 62229-50-9 / Epidermal Growth Factor; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2931506
  •  go-up   go-down


40. Mori K, Iwata J, Miyazaki M, Osada H, Tange Y, Yamamoto T, Aiko Y, Tamura M, Shiroishi T: Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells. Neurol Med Chir (Tokyo); 2010;50(7):545-53
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells.
  • Transduction of the suicide gene of Herpes simplex virus thymidine kinase (Hsv-tk) into glioma cells or neural stem cells combined with pro-drug ganciclovir (GCV) treatment has been effective to treat experimental glioma in the rat through the bystander effect.
  • Bone marrow stromal cells (MSCs) in the adult bone marrow have tropism for brain tumors and act as tumor stromal cells.
  • Whether adult MSCs expressing Hsv-tk can also act as effector cells of the bystander killing effect on murine glioma cells was investigated.
  • The animals co-inoculated with 9L glioma cells and MSCs/tk(+) showed significant retardation of tumor growth and prolongation of survival time compared with the animals with 9L glioma cells and MSCs/tk(-).
  • Quantitative findings were established of the novel effects of adult MSCs/tk(+) as effector cells of the bystander killing effect on glioma cells.
  • [MeSH-major] Antiviral Agents / pharmacology. Bone Marrow Cells. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Bystander Effect / genetics. Cell Survival / genetics. Ganciclovir / pharmacology. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Glioma / genetics. Glioma / pathology. Simplexvirus / enzymology. Simplexvirus / genetics. Stromal Cells. Thymidine Kinase / genetics
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Division / genetics. Cell Line, Tumor. Humans. In Vitro Techniques. Lac Operon / genetics. Male. Mice. Neoplasm Transplantation. Rats. Rats, Inbred F344

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671379.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


41. Khanna A, Reddy SS, Jan M, Totey S, Rao TV, Rao SA, Naik AL, Totey S, Venkataramana NK: Establishment of a brain tumor tissue repository in India: maintaining quality standards. J Stem Cells; 2010;5(2):89-101
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a brain tumor tissue repository in India: maintaining quality standards.
  • Tumor tissue repositories (TTRs) play a pivotal role in both basic and translational research by acting as a conduit to facilitate innovative research, thereby providing solutions to treat the incurable disease--'Cancer'.
  • One of the fundamental requirements to achieve this goal would be the acquisition of high quality tumor tissue specimens that are stored in such a manner that its integrity is preserved.
  • To address this, we have initiated an effort to build a tumor tissue repository of brain tumor tissues in the Southern part of the Indian sub-continent.
  • One of the cardinal features of brain tumors is the heterogeneity, both phenotypically and genotypically.
  • Moreover, significant gaps exist in current understanding of the molecular pathways involved in the genesis, progression, and biological and clinical behavior of brain tumors.
  • To our knowledge, such a structured initiative to store brain tumor samples is the first of its kind in the India.
  • [MeSH-major] Biomedical Research / organization & administration. Brain Neoplasms / pathology. Quality Control. Tissue Banks / organization & administration. Tissue Banks / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Cryopreservation. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Specimen Handling. Tissue Donors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22049619.001).
  • [ISSN] 1556-8539
  • [Journal-full-title] Journal of stem cells
  • [ISO-abbreviation] J Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


42. Lotze C, Schüler F, Krüger WH, Hirt C, Kirsch M, Vogelgesang S, Schmidt CA, Dölken G: Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro Oncol; 2005 Oct;7(4):508-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.
  • Graft-versus-leukemia effects (GvL) contribute substantially to eradication of hematological malignancies after allogeneic stem cell transplantation.
  • Few data are available describing GvL activity within the brain.
  • The brain was irradiated with 44 Gy, anti-CD20 antibodies were given, and the immunosuppression was withdrawn.
  • [MeSH-major] Antibodies / therapeutic use. Brain Neoplasms / radiotherapy. Graft vs Leukemia Effect / physiology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Humans. Male. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 2001;82:133-85 [11447762.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):843-6 [14520432.001]
  • [Cites] Blood. 2004 Jan 15;103(2):725-31 [12947008.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):503-6 [9313885.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):185-90 [10350348.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • (PMID = 16212815.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC1871735
  •  go-up   go-down


43. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT: Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2007 Aug;13(8):975-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
  • We characterized the natural history of metastatic renal cell carcinoma (RCC) and identified prognostic factors among patients who did or did not undergo allogeneic hematopoietic stem cell transplantation (HSCT).
  • Overall survival rates were comparable between the HSCT and no-HSCT groups (excluding patients with poor performance status or brain metastasis from the latter group) at a median 17.4 months of follow-up (P=.92).
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Hematopoietic Stem Cell Transplantation. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Mortality. Neoplasm Metastasis. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Treatment Refusal

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640602.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME: Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol; 2008 Jun 20;26(18):3015-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
  • PURPOSE: Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells.
  • Better outcome was associated with gene clusters characterizing features of tumor-host interaction including tumor vascularization and cell adhesion, and innate immune response.
  • CONCLUSION: This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioblastoma / pathology. Glioblastoma / therapy. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Genes, Homeobox. Humans. Middle Aged. Multigene Family. Radiation Tolerance

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565887.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


45. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, Renault-Mihara F, Thirant C, Leonard N, Berhneim A, Mihalescu-Maingot M, Haiech J, Bièche I, Moura-Neto V, Daumas-Duport C, Junier MP, Chneiweiss H: CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer; 2010;10:66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors.
  • BACKGROUND: Tumor initiating cells (TICs) provide a new paradigm for developing original therapeutic strategies.
  • METHODS: We screened for TICs in 47 human adult brain malignant tumors.
  • Cells forming floating spheres in culture, and endowed with all of the features expected from tumor cells with stem-like properties were obtained from glioblastomas, medulloblastoma but not oligodendrogliomas.
  • Xenografts of fewer than 500 cells in Nude mouse brains induced a progressively growing tumor.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD15 / biosynthesis. Antigens, CD34 / biosynthesis. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Glycoproteins / biosynthesis. Neoplastic Stem Cells / cytology. Neurons / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Peptides. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2006 Jan;111(1):29-38 [16320026.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):961-73 [17204602.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2695-706 [17057735.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2897-904 [17504989.001]
  • [Cites] PLoS One. 2008;3(11):e3655 [18985161.001]
  • [Cites] Cell Stem Cell. 2009 May 8;4(5):440-52 [19427293.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2373-82 [19544474.001]
  • [Cites] Prog Neurobiol. 2000 Dec;62(5):443-73 [10869779.001]
  • [Cites] Ann Pathol. 2000 Oct;20(5):413-28 [11084409.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1652-8 [11245479.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):289-96 [11718261.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Trends Neurosci. 2004 Mar;27(3):148-54 [15036880.001]
  • [Cites] Nature. 2004 Jul 15;430(6997):350-6 [15254537.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • (PMID = 20181261.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD15; 0 / Antigens, CD34; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2841664
  •  go-up   go-down


46. Hruska M, Keefe J, Wert D, Tekinay AB, Hulce JJ, Ibañez-Tallon I, Nishi R: Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci; 2009 Nov 25;29(47):14847-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons.
  • Vertebrate alpha-bungarotoxin-like molecules of the Ly-6 superfamily have been implicated as balancers of activity and survival in the adult nervous system.
  • One of these genes, an ortholog of prostate stem cell antigen (psca), is barely detectable at embryonic day (E) 8, before neuronal cell loss in the ciliary ganglion, but increases >100-fold as the number of neurons begins to decline between E9 and E14.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurobiol. 2002 Dec;53(4):524-34 [12436417.001]
  • [Cites] J Comp Neurol. 2002 Oct 7;452(1):80-92 [12205711.001]
  • [Cites] Genomics. 2003 Jan;81(1):26-33 [12573258.001]
  • [Cites] Hum Mol Genet. 2003 Nov 15;12(22):3017-24 [14506129.001]
  • [Cites] J Physiol. 1972 May;222(3):691-713 [4338175.001]
  • [Cites] J Physiol. 1974 Sep;241(3):737-49 [4373568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Nov;73(11):3952-6 [186781.001]
  • [Cites] Nature. 1978 Jan 26;271(5643):364-6 [622175.001]
  • [Cites] J Comp Neurol. 1979 Sep 15;187(2):425-46 [489787.001]
  • [Cites] Brain Res. 1981 Apr;227(2):283-6 [7225894.001]
  • [Cites] J Neurosci. 1987 Dec;7(12):3840-9 [2826719.001]
  • [Cites] Brain Res. 1988 Mar 15;444(1):189-94 [2834023.001]
  • [Cites] Dev Biol. 1992 Feb;149(2):295-306 [1730386.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4424-31 [7876208.001]
  • [Cites] Neuron. 1995 Oct;15(4):857-66 [7576634.001]
  • [Cites] Immunol Cell Biol. 1995 Aug;73(4):277-96 [7493764.001]
  • [Cites] Methods Cell Biol. 1996;51:185-218 [8722477.001]
  • [Cites] Methods Cell Biol. 1997;52:179-214 [9379950.001]
  • [Cites] Eur J Biochem. 1999 Sep;264(2):281-6 [10491072.001]
  • [Cites] Mol Cell Neurosci. 2006 Feb;31(2):232-42 [16236524.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):238-45 [16575903.001]
  • [Cites] Neuron. 2006 Sep 7;51(5):587-600 [16950157.001]
  • [Cites] Life Sci. 2007 May 30;80(24-25):2243-7 [17280689.001]
  • [Cites] J Neurosci. 2007 Oct 24;27(43):11501-9 [17959793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4477-82 [19246390.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] J Neurosci. 1998 Sep 1;18(17):6871-81 [9712657.001]
  • [Cites] Genomics. 1998 Nov 1;53(3):365-8 [9799603.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):692-704 [9880590.001]
  • [Cites] J Neurophysiol. 1999 Jan;81(1):111-20 [9914272.001]
  • [Cites] Neuron. 1999 May;23(1):105-14 [10402197.001]
  • [Cites] Mol Cell Neurosci. 2000 Feb;15(2):113-22 [10673321.001]
  • [Cites] J Neurosci. 2000 Aug 15;20(16):6117-24 [10934261.001]
  • [Cites] J Neurophysiol. 2000 Sep;84(3):1314-29 [10980005.001]
  • [Cites] J Neurosci. 2001 Feb 1;21(3):771-81 [11157063.001]
  • [Cites] Dev Biol. 2001 May 15;233(2):437-48 [11336506.001]
  • [Cites] Neuron. 2002 Mar 14;33(6):893-903 [11906696.001]
  • [Cites] Mol Pharmacol. 2003 Feb;63(2):311-24 [12527802.001]
  • (PMID = 19940180.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA017784; United States / NIDA NIH HHS / DA / DA017784-04; United States / NIDA NIH HHS / DA / R01 DA017784-03; United States / NIDA NIH HHS / DA / DA17784; United States / NIDA NIH HHS / DA / R01 DA017784-02; United States / NCRR NIH HHS / RR / P20 RR016435; United States / NIDA NIH HHS / DA / DA017784-03; United States / NIDA NIH HHS / DA / DA017784-02; United States / NCRR NIH HHS / RR / 5 P20 RR016435; United States / NIDA NIH HHS / DA / R01 DA017784-04; United States / NIDA NIH HHS / DA / R01 DA017784-01A2; United States / NIDA NIH HHS / DA / DA017784-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Avian Proteins; 0 / Chrna7 protein, mouse; 0 / GPI-Linked Proteins; 0 / Lynx1 protein, mouse; 0 / Lynx2 protein, mouse; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Neuropeptides; 0 / Neurotoxins; 0 / Nicotinic Agonists; 0 / Nicotinic Antagonists; 0 / Psca protein, mouse; 0 / Receptors, Nicotinic; 0 / alpha7 Nicotinic Acetylcholine Receptor
  • [Other-IDs] NLM/ NIHMS174829; NLM/ PMC2848080
  •  go-up   go-down


47. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, Sitbon E, Lithwick Yanai G, Elyakim E, Cholakh H, Gibori H, Spector Y, Bentwich Z, Barshack I, Rosenfeld N: MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol; 2009 Jul;19(3):375-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.
  • A recurring challenge for brain pathologists is to diagnose whether a brain malignancy is a primary tumor or a metastasis from some other tissue.
  • The accurate diagnosis of brain malignancies is essential for selection of proper treatment.
  • Using microRNA expression profiling, we found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are over-expressed, specifically in brain primary tumors, as compared to primary tumors from other tissues and their metastases to the brain.
  • By considering the expression of only these two microRNAs, it is possible to distinguish between primary and metastatic brain tumors with very high accuracy.
  • These microRNAs thus represent excellent biomarkers for brain primary tumors.
  • Previous reports have found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are expressed more strongly in developing neurons and brain than in adult brain.
  • Thus, their specific over-expression in brain primary tumors supports a functional role for these microRNAs or a link between neuronal stem cells and brain tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. MicroRNAs / genetics. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Area Under Curve. Diagnosis, Differential. Gene Expression. Humans. Oligonucleotide Array Sequence Analysis. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R183-90 [16244316.001]
  • [Cites] Biotechniques. 2005 Oct;39(4):519-25 [16235564.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2202-7 [16882971.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1419-25 [16983573.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):380-5 [17259983.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Genome Res. 2007 Sep;17(9):1245-53 [17690206.001]
  • [Cites] Indian J Pathol Microbiol. 2007 Jul;50(3):478-81 [17883112.001]
  • [Cites] RNA. 2007 Oct;13(10):1668-74 [17698639.001]
  • [Cites] Nat Genet. 2007 Oct;39(10):1191-2 [17898777.001]
  • [Cites] Mol Ther. 2007 Dec;15(12):2070-9 [17878899.001]
  • [Cites] Genome Biol. 2007;8(8):R173 [17711588.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):281-91 [18398573.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):197-208 [12061725.001]
  • [Cites] RNA. 2003 Oct;9(10):1274-81 [13130141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):13985-90 [15306687.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Neurosurgery. 1981 Jan;8(1):26-30 [7207769.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2433-7 [6182974.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2349-54 [6640506.001]
  • [Cites] Cancer. 1988 May 1;61(9):1926-34 [3355984.001]
  • [Cites] Histopathology. 1989 Apr;14(4):359-68 [2472343.001]
  • [Cites] Neurosurgery. 1991 Jan;28(1):8-14; discussion 14-5 [1994286.001]
  • [Cites] N Engl J Med. 1992 Jul 9;327(2):107-16 [1351250.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):917-20 [10506444.001]
  • [Cites] FEBS Lett. 2005 Jan 17;579(2):318-24 [15642338.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • (PMID = 18624795.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2728890
  •  go-up   go-down


48. Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M, Chinot O, Durand A, Figarella-Branger D: Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien); 2009 Aug;151(8):947-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients.
  • OBJECT: This study was undertaken to analyze outcomes and to assess the prognostic impact of age, location, surgery, radiotherapy (RT), and histopathology in a series of adult infratentorial ependymomas.
  • METHODS: This was a retrospective study of a population of 106 adult patients with infratentorial ependymomas diagnosed between 1990 and 2004.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Stem / surgery. Cerebellum / surgery. Ependymoma / surgery. Infratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Neurosurgical Procedures / mortality. Neurosurgical Procedures / statistics & numerical data. Outcome Assessment (Health Care) / methods. Postoperative Complications / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499166.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


49. Amthauer H, Wurm R, Kuczer D, Ruf J, Michel R, Eisenacher J, Stockhammer F, Denecke T, Felix R, Plotkin M: Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor. Clin Nucl Med; 2006 Apr;31(4):189-92
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of image fusion with MRI for the interpretation of I-123 iodo-methyl-tyrosine scans in patients with suspected recurrent or residual brain tumor.
  • PURPOSE: The aim of the study was to investigate the impact of MR/SPECT image fusion on the interpretation of I-123 iodo-methyl-tyrosine (IMT) SPECT examinations in patients with pretreated brain tumors.
  • Tumor localization and extent were evaluated and correlated with histopathology or clinical follow up, including MR imaging.
  • RESULTS: In 10 of 45 (22%) patients, image fusion had a significant impact on the interpretation of scans: 5 suspected SPECT findings were correctly classified as physiological or therapy-related; in another 5 patients, image fusion added relevant clinical information on tumor extent (infiltration of the contralateral hemisphere n = 3, infiltration of the brain stem n = 2).
  • [MeSH-major] Brain Neoplasms / pathology. Iodine Radioisotopes. Magnetic Resonance Imaging. Methyltyrosines. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550008.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 14684-02-7 / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


50. Tabatabai G, Herrmann C, von Kürthy G, Mittelbronn M, Grau S, Frank B, Möhle R, Weller M, Wick W: VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain; 2008 Oct;131(Pt 10):2579-95
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells.
  • Exposure of human cerebral endothelial cells (SV-HCEC), human microvascular endothelial cells (HMEC) and brain tumour endothelial cells derived from human glioblastomas (BTEC) to supernatants of glioma cells and primary glioma cells (SN-G) induced the expression of E-selectin (CD62E).
  • Tissue microarray sampling normal brain tissue and astrocytomas of WHO grades II-IV revealed a selective expression of CD62E on endothelial cells of tumour vessels.
  • [MeSH-major] Adult Stem Cells / metabolism. E-Selectin / metabolism. Endothelial Cells / metabolism. Glioma / metabolism. Hematopoietic Stem Cells / metabolism. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Autoantibodies / pharmacology. Cell Hypoxia. Cell Line, Tumor. Cell Migration Inhibition. Cell Movement. Coculture Techniques. Gene Expression. Humans. Mice. Mice, Mutant Strains. NF-kappa B / metabolism. Neoplasm Transplantation. Signal Transduction / physiology. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689869.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / E-Selectin; 0 / NF-kappa B; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


51. Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD, Robertson KD: Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest; 2008 Sep;88(9):910-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
  • Malignant gliomas are the most common primary brain tumors in adults and the second most common tumor in children.
  • Morbidity and mortality are high in glioma patients because tumors are resistant to treatment and are highly invasive into surrounding brain tissue rendering complete surgical resection impossible.
  • Here, we study the expression of cystatin E/M in normal brain and show that it is highly and moderately expressed in oligodendrocytes and astrocytes, respectively, but not in neurons.
  • In contrast, 78% of 28 primary brain tumors demonstrated reduced/absent cystatin E/M expression using a tissue microarray and this reduced expression correlated with CST6 promoter hypermethylation.
  • Interestingly, CST6 was expressed in neural stem cells (NSC) and markedly induced upon differentiation, whereas a glioma tumor initiating cell (TIC) line was completely blocked for CST6 expression by promoter methylation.
  • Analysis of primary pediatric brain tumor-derived lines also showed CST6 downregulation and methylation in nearly 100% of 12 cases.
  • These results demonstrate that epigenetic silencing of CST6 is frequent in adult and pediatric brain tumors and occurs in TICs, which are thought to give rise to the tumor.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Apr 28;235(2):159-76 [15893421.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15893-9 [16565075.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Neuron. 2000 Nov;28(2):385-97 [11144350.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):922-34 [12065604.001]
  • [Cites] J Neurooncol. 2002 May;58(1):21-32 [12160137.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7899-909 [16912163.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1429-39 [17081116.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1233-42 [17043665.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2409-23 [16952911.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2621-34 [17043644.001]
  • [Cites] Oncogene. 2007 May 10;26(21):3089-94 [17099723.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):447-60 [17610375.001]
  • [Cites] Nat Protoc. 2007;2(9):2265-75 [17853883.001]
  • [Cites] Biochim Biophys Acta. 2007 Dec;1776(2):125-37 [17868999.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):69-80 [18167341.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):21-30 [18184972.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):655-60 [12684707.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):203-15 [15674478.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):175-82 [16356477.001]
  • [Cites] Life Sci. 2006 Jan 18;78(8):898-907 [16150465.001]
  • [Cites] Nat Rev Genet. 2002 Sep;3(9):662-73 [12209141.001]
  • [Cites] Brain Tumor Pathol. 2002;19(1):15-22 [12455884.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8705-12 [12483523.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 [12591989.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] J Pediatr Nurs. 2003 Apr;18(2):96-102 [12720206.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):134-42 [12850376.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1911-9 [14578190.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] J Neurosci Res. 2003 Dec 15;74(6):838-51 [14648588.001]
  • [Cites] Neurol Clin. 2003 Nov;21(4):897-913 [14743655.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2206-15 [14676833.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2224-30 [14730346.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118-31 [15313584.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6957-64 [15466187.001]
  • [Cites] Development. 1989 Feb;105(2):387-400 [2680425.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Neurosci Lett. 1996 Apr 26;208(3):171-4 [8733297.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Clin Exp Metastasis. 1996 Sep;14(4):344-50 [8878408.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10853-8 [9099741.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):89-93 [9738504.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):798-802 [10029065.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):159-73 [16442709.001]
  • (PMID = 18607344.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA114229-04; United States / NCI NIH HHS / CA / R01 CA114229-03; United States / NCI NIH HHS / CA / R01 CA114229; United States / NCI NIH HHS / CA / CA114229-03; United States / NCI NIH HHS / CA / R01CA102289; United States / NCI NIH HHS / CA / R01 CA102289; United States / NCI NIH HHS / CA / CA114229-04; United States / NCI NIH HHS / CA / R01CA114229
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CST6 protein, human; 0 / Cystatin M; 0 / Cystatins; 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS59304; NLM/ PMC2574902
  •  go-up   go-down


52. Doyle DM, Einhorn LH: Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1361-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.
  • CNS metastases have been managed with whole brain radiotherapy (WBRT) and concomitant cisplatin-based combination chemotherapy.
  • CONCLUSION: Whole brain radiotherapy is not innocuous in young patients with germ cell tumors and can cause late CNS toxicity.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Neoplasms, Germ Cell and Embryonal / radiotherapy. Radiation Injuries / complications. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / blood. Choriocarcinoma / drug therapy. Choriocarcinoma / radiotherapy. Choriocarcinoma / secondary. Chorionic Gonadotropin / blood. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / etiology. Lung Neoplasms / secondary. Male. Neoplasm Proteins / blood. Radiotherapy Dosage. Salvage Therapy / methods. Stem Cell Transplantation. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1300-2 [18374219.001]
  • (PMID = 18374223.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Cancer stem cells are currently a target for the treatment of malignant tumors.
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the CNS.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


54. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
  • CONCLUSION: BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


55. Kroonen J, Nguyen-Khac MT, Deprez M, Rogister B, Robe P: [Glioblastoma, an example of translational research?]. Rev Med Liege; 2008 May-Jun;63(5-6):251-6
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the adult, GBM is the most frequent and most aggressive tumour of the Central Nervous System.
  • GBM stem cells have been recently described and it was demonstrated that they are specifically implied in the experimental tumorigenesis.
  • It is thus very attractive to speculate on a possible relationship between these GBM stem cells and the neural stem cells which are persisting in the neurogenic zones of the adult brain.
  • In this review, we formulate and discuss the hypothesis by which, in a patient with GBM, malignant stem cells might be present in the neurogenic zones, away from the tumour mass.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Biomedical Research. Humans. Neoplastic Stem Cells

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669189.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Belgium
  • [Number-of-references] 27
  •  go-up   go-down


56. Chen H, Huang Q, Zhai DZ, Dong J, Wang AD, Lan Q: [CDK1 expression and effects of CDK1 silencing on the malignant phenotype of glioma cells]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):484-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our previous cDNA array data have shown that expression level of CDK1 increased along with the malignant progression of ganglioglioma, and decreased with the differentiation process of neural stem cells.
  • METHODS: Glioma tissue array was constructed, which was composed of surgical specimens of gliomas with different malignancy grades, glioma xenografts in nude mice, cellular spheroids of brain tumor stem cells, normal neural stem cells and glioma cell line.
  • CDK1 expression in human brain glioma cell line and relevant xenogeneic graft tumor was inhibited by retroviral vectors expressing short hairpin RNAs (shRNAs).
  • The positive expression rates of CDK1 in human brain glioma tissues were 22.2% (grade I), 40.0% (grade II), 69.6% (grade III) and 78.6% (grade IV), P = 0.01, respectively.
  • The positive expression rate of CDK1 in glioma cell line and implanted xenografts was similar as the clinical tumors with high malignancy, and higher than those in neural stem cells and brain tumor stem cells (P = 0.0014).
  • Expression of CDK1 was high in human fetal brain tissues and bone marrows of nude mice, but low in normal adult human brain tissues.
  • Downregulation of CDK1 inhibited the proliferation activities notably both in SHG-44 cells in vitro and relevant xenogeneic graft tumors, and induced apoptosis of tumor cells prominantly as well.
  • [MeSH-major] Brain Neoplasms / metabolism. CDC2 Protein Kinase / metabolism. Cell Differentiation / drug effects. Gene Silencing. Glioma / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Stem Neoplasms / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Ganglioglioma / genetics. Ganglioglioma / metabolism. Ganglioglioma / pathology. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Nude. Neoplasm Staging. Neoplasm Transplantation. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069625.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


57. Duntsch C, Zhou Q, Weimar JD, Frankel B, Robertson JH, Pourmotabbed T: Up-regulation of neuropoiesis generating glial progenitors that infiltrate rat intracranial glioma. J Neurooncol; 2005 Feb;71(3):245-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate adult neural stem cell (NSC) biology in relation to glioma, the C6 glioma cell line was tagged with green fluorescent protein (GFP) and inoculated into the brain of adult rats.
  • The in vivo biological response of the brain to glioma was studied using immunohistochemical analysis of the subventricular zone (SVZ), peritumoral areas, and glioma.
  • Nestin immunoreactive cells were found infiltrating glioma, but the distribution of abnormal immunoreactivity was restricted to the dorsal and medial border of the tumor relative to the ipsilateral ventricle.
  • Furthermore, a dense contiguous population of nestin immunoreactive cells could be found streaming from ipsilateral dorsal tip of the SVZ, tracking along the ventral margin of the corpus callosum, and fanning out to encompass and infiltrate the proximal tumor border.
  • Although most cells were either nestin or glial fibrillary acidic protein (GFAP) immunoreactive in the SVZ and along the ventral margin of the corpus callosum, the number of cells co-expressing both markers increased proportionally as the tumor was approached so that the predominant cell population along the proximal tumor border was GFAP immunoreactive.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology. Neuroglia / metabolism. Neuroglia / pathology. Stem Cells / metabolism
  • [MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Cell Movement. Cerebral Ventricles / pathology. Disease Models, Animal. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry. Intermediate Filament Proteins / metabolism. Neoplasm Transplantation. Nerve Tissue Proteins / metabolism. Nestin. Rats. Rats, Inbred WF. Rats, Sprague-Dawley. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1999 Sep 4;840(1-2):153-7 [10517963.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):59-67 [10360479.001]
  • [Cites] J Neurosci. 1988 Apr;8(4):1144-51 [3357014.001]
  • [Cites] Trends Neurosci. 1997 Dec;20(12):570-7 [9416670.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Neuron. 1993 Jul;11(1):173-89 [8338665.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Brain Res. 1999 Aug 14;838(1-2):1-10 [10446310.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Virchows Arch B Cell Pathol. 1978 Jul 14;28(1):77-85 [97859.001]
  • [Cites] Neuroreport. 1994 Oct 3;5(15):1885-8 [7841369.001]
  • [Cites] J Neurosci. 1996 Dec 1;16(23):7599-609 [8922416.001]
  • [Cites] Neurosurgery. 1990 Apr;26(4):622-8 [2330084.001]
  • [Cites] J Neurosurg. 1981 Apr;54(4):461-7 [7205347.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):168-75; discussion 175-6 [11440439.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):31-44 [12952284.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] Neuroreport. 1999 Apr 6;10(5):1007-11 [10321476.001]
  • [Cites] Brain Res. 1997 Sep 12;768(1-2):1-9 [9369294.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] Pediatr Neurosurg. 1992;18(5-6):310-4 [1476942.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):453-64 [7593171.001]
  • [Cites] J Neurosci. 1996 Apr 15;16(8):2649-58 [8786441.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):683-8 [11723374.001]
  • [Cites] Trends Neurosci. 1994 Apr;17(4):138-42 [7517589.001]
  • [Cites] Mol Cell Neurosci. 1995 Oct;6(5):474-86 [8581317.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):151-60 [9892097.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):459-65 [11565868.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):421-9 [10931528.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1529-37 [9771921.001]
  • [Cites] J Neurosurg. 1980 Dec;53(6):808-15 [7003068.001]
  • (PMID = 15735912.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin
  •  go-up   go-down


58. Hoei-Hansen CE, Sehested A, Juhler M, Lau YF, Skakkebaek NE, Laursen H, Rajpert-de Meyts E: New evidence for the origin of intracranial germ cell tumours from primordial germ cells: expression of pluripotency and cell differentiation markers. J Pathol; 2006 May;209(1):25-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We applied recent knowledge from gonadal germ cell tumours and analysed expression of a wide panel of stem cell-related proteins (C-KIT, OCT-3/4 (POU5F1), AP-2gamma (TFAP2C), and NANOG) and developmentally regulated germ cell-specific proteins (including MAGE-A4, NY-ESO-1, and TSPY).
  • Stem cell related proteins were highly expressed in intracranial germ cell tumours, and many similarities were detected with their gonadal equivalents, including a close similarity with primordial germ cells.
  • The expression of genes associated with embryonic stem cell pluripotency in CNS germ cell tumours strongly suggests that these tumours are derived from cells that retain, at least partially, an embryonic stem cell-like phenotype, which is a hallmark of primordial germ cells.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplastic Stem Cells / pathology. Pluripotent Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, Differentiation / metabolism. Cell Differentiation. Child. Child, Preschool. Embryonal Carcinoma Stem Cells. Female. Gene Expression. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Male. Neoplasm Proteins / metabolism. Stromal Cells / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16456896.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Neoplasm Proteins; 0 / Transcription Factors
  •  go-up   go-down


59. Glantz M, Kesari S, Recht L, Fleischhack G, Van Horn A: Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. Semin Oncol; 2009 Aug;36(4 Suppl 2):S17-24
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM), the most common malignant primary brain tumor in adults, carries a poor prognosis, with median survival generally less than 1 year.
  • Although initial therapy often eradicates the bulk of the tumor, disease recurrence, usually within 2 cm of the original tumor, is almost inevitable.
  • An increasing body of preclinical data suggests that these cells may correspond to stem cells derived from the subventricular zone (SVZ), which migrate to tumor sites and contribute to glioma growth and recurrence.
  • Therapeutic targeting of SVZ stem cell populations via cerebrospinal fluid (CSF)-directed therapy may provide a means for limiting tumor recurrence.
  • This approach has proved successful in the treatment of medulloblastoma, another brain tumor thought to be derived from stem cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / methods. Humans. Injections, Spinal. Neoplastic Stem Cells. Research Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660679.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Chu L, Huang Q, Zhai DZ, Zhu Q, Huo HM, Dong J, Qian ZY, Wang AD, Lan Q, Gao YL: [Expression and significance of ABCG2 in human malignant glioma]. Ai Zheng; 2007 Oct;26(10):1090-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: ATP-binding cassette transporter protein ABCG2 is a marker derived from hematopoietic stem cells.
  • METHODS: A microarray chip containing glioma tissues of different malignant grades, implanted glioma xenografts in nude mice, spheroids of glioma cell lines and glioma stem cells was prepared and examined for the expression of ABCG2 with immunohistochemical staining.
  • The positive rate of ABCG2 was 100% in implanted glioma xenografts in nude mice, gliomas stem cells, and neural stem cells.
  • CONCLUSIONS: ABCG2 is overexpressed in glioma stem cells, glioma tissues of higher grades, and implanted glioma xenografts.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Neoplasm Proteins / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Bone Marrow Cells / metabolism. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Stem Cells / metabolism. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927879.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


61. Helton KJ, Phillips NS, Khan RB, Boop FA, Sanford RA, Zou P, Li CS, Langston JW, Ogg RJ: Diffusion tensor imaging of tract involvement in children with pontine tumors. AJNR Am J Neuroradiol; 2006 Apr;27(4):786-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Conventional MR imaging permits subcategorization of brain stem tumors by location and focality; however, assessment of white matter tract involvement by tumor is limited.
  • Diffusion tensor imaging (DTI) is a promising method for visualizing white matter tract tumor involvement supratentorially.
  • CONCLUSION: DTI provided superior visualization and quantification of tumor involvement in motor, sensory, and transverse pontine tracts, compared with information provided by conventional MR imaging.
  • Further prospective studies are warranted to assess the ability of DTI to delineate tumor focality and improve risk stratification in children with pontine tumors.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Infant, Newborn. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16611765.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH: Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest; 2008 Aug;88(8):808-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential.
  • These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells.
  • Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells.
  • Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / immunology. Glioblastoma / immunology. Glycoproteins / metabolism. Neoplastic Stem Cells / immunology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Brain / pathology. Cells, Cultured. Drug Resistance, Neoplasm / immunology. Female. Gene Expression Profiling. Humans. Male. Mice. Mice, SCID. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560366.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


63. Fangusaro J: Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol; 2009 Nov;24(11):1409-17
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric high-grade gliomas represent approximately 10% of all pediatric brain tumors.
  • Similar to adult high-grade gliomas, they behave very aggressively, and these children have a very poor prognosis despite a variety of therapies that include chemotherapy and radiotherapy.
  • [MeSH-major] Brain Neoplasms. Brain Stem Neoplasms. Glioma
  • [MeSH-minor] Child. Humans. Models, Neurological. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638636.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


64. Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, Garbe S, Steinfarz B, Pietsch T, Steindler DA, Schramm J, Herrlinger U, Brüstle O, Scheffler B: Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol; 2010 Aug;68(2):264-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual tumor cells are unique cellular targets in glioblastoma.
  • Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection.
  • In this study, residual tumor cells were derived via experimental biopsy of the resection margin after standard neurosurgery for direct comparison with samples from the routinely resected tumor tissue.
  • In vitro analysis of proliferation, invasion, stem cell qualities, GBM-typical antigens, genotypes, and in vitro drug and irradiation challenge studies revealed these cells as unique entities.
  • Our findings suggest a need for characterization of residual tumor cells to optimize diagnosis and treatment of GBM.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695020.001).
  • [ISSN] 1531-8249
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS055165; United States / NINDS NIH HHS / NS / NS055165
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ NIHMS686096; NLM/ PMC4445859
  •  go-up   go-down


65. Meregalli M, Farini A, Belicchi M, Torrente Y: CD133(+) cells isolated from various sources and their role in future clinical perspectives. Expert Opin Biol Ther; 2010 Nov;10(11):1521-8
Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initially, the expression of CD133 antigen was seen only in the hematopoietic derived CD34(+) stem cells.
  • CD133(+) neurosphere cells isolated from brain are able to differentiate into both neurons and glial cells.
  • These data suggested that CD133 could be a specific marker for various stem and progenitor cell populations.
  • OBJECTIVES: The main goal would be to describe the role for CD133 as a marker of stem cells able to engraft and differentiate, to form functional non-hematopoietic adult lineages and contribute to disease amelioration via tissue regeneration.
  • RESULTS/CONCLUSION: In conclusion, since the rise of CD133 antigen as a suitable stem cell marker, the possible use of CD133(+) stem cells in therapeutic applications has opened a new promising field in the treatment of degenerating diseases.
  • The human circulating cells expressing the CD133 antigen behave as a stem cell population capable of commitment to hematopoietic, endothelial and myogenic lineages.
  • [MeSH-major] Antigens, CD / analysis. Glycoproteins / analysis. Peptides / analysis. Stem Cell Transplantation. Stem Cells / chemistry
  • [MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Clinical Trials as Topic. Epithelial Cells / chemistry. Hematopoietic Stem Cells / chemistry. Humans. Ischemia / surgery. Mice. Mice, Inbred NOD. Mice, SCID. Muscular Dystrophies / surgery. Neoplasm Transplantation. Neoplasms / surgery. Neoplastic Stem Cells / chemistry. Organ Specificity. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932225.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


66. MacNally SP, Rutherford SA, King AT, Freeman S, Thorne J, Mawman D, O'Driscoll MP, Evans DG, Ramsden RT: Outcome from surgery for vestibular schwannomas in children. Br J Neurosurg; 2009 Jun;23(3):226-31
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hearing rehabilitation can be successful by utilising cochlear implants and auditory brain stem implants (ABI) as appropriate.
  • Overall there is a low complication rate and results are comparable with adult series.
  • [MeSH-minor] Adolescent. Auditory Brain Stem Implants. Auditory Threshold / physiology. Child. Cochlear Implants. Codon, Nonsense / genetics. Cranial Nerve Neoplasms / surgery. Facial Nerve Diseases / surgery. Female. Hearing Disorders / prevention & control. Humans. Male. Neoplasm Recurrence, Local / pathology. Outcome Assessment (Health Care). Postoperative Complications / prevention & control. Postoperative Complications / rehabilitation. Prognosis. Retrospective Studies. Speech Discrimination Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Neurosurg. 2009 Jun;23(3):232-3 [19533455.001]
  • (PMID = 19533454.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon, Nonsense
  •  go-up   go-down


67. Croitoru-Lamoury J, Williams KR, Lamoury FM, Veas LA, Ajami B, Taylor RM, Brew BJ: Neural transplantation of human MSC and NT2 cells in the twitcher mouse model. Cytotherapy; 2006;8(5):445-58
MedlinePlus Health Information. consumer health - Leukodystrophies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Accumulating evidence has demonstrated that the NT2 embryonal carcinoma cell line and multipotential stem cells found in BM, mesenchymal stromal cells (MSC), have the ability to differentiate into a wide variety of cell types.
  • This study was designed to explore the efficacy of these two human stem cell types as a graft source for the treatment of demyelinating disorders such as Krabbe's disease and multiple sclerosis (MS).
  • METHODS: We examined the engraftment and in vivo differentiation of adult MSC and NT2 cells after transplantation into two demyelinating environments, the neonatal and postnatal twitcher mouse brain.
  • RESULTS: Both types of xenografts led to anatomical integration, without tumor formation, and remained viable in the normal and twitcher mouse brain, showing differentiation into neurons, astrocytes and oligodendrocytes.
  • DISCUSSION: This study represents a platform for further stem cell transplantation studies in the twitcher model and potentially has important therapeutic implications.
  • [MeSH-major] Brain / metabolism. Cell Differentiation. Leukodystrophy, Globoid Cell / therapy. Mesoderm / metabolism. Multipotent Stem Cells / metabolism. Stem Cell Transplantation
  • [MeSH-minor] Animals. Astrocytes / metabolism. Astrocytes / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Disease Models, Animal. Humans. Mice. Mice, Mutant Strains. Neoplasm Transplantation / methods. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Neurons / metabolism. Neurons / pathology. Oligodendroglia / metabolism. Oligodendroglia / pathology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050249.001).
  • [ISSN] 1465-3249
  • [Journal-full-title] Cytotherapy
  • [ISO-abbreviation] Cytotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther; 2006 Mar;5(1):40-7
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
  • BACKGROUND: Brainstem glioma carries the worst prognosis of all malignancies of the brain.
  • Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years.
  • Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG).
  • CONCLUSION: Antineoplastons contributed to more than a 5-year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients.
  • [MeSH-major] Benzeneacetamides / administration & dosage. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Glutamine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Phenylacetates / administration & dosage. Piperidones / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Female. Follow-Up Studies. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484713.001).
  • [ISSN] 1534-7354
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10
  •  go-up   go-down


69. Abe M, Tokumaru S, Tabuchi K, Kida Y, Takagi M, Imamura J: Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg; 2006;42(2):81-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five patients were treated with one to two sequential courses of high-dose chemotherapy with peripheral blood stem cell transplantation.
  • The reduction in tumor size after SRT was often remarkable.
  • In contrast, all 8 patients with metastasis had new lesions either in the spinal canal or on the surface of the brain outside the target area of SRT.
  • One patient had brainstem edema after SRT causing bulbar palsy and quadriparesis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Medulloblastoma / therapy. Neoplasm Recurrence, Local / therapy. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Peripheral Blood Stem Cell Transplantation. Radiotherapy Dosage. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16465076.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


70. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer; 2005 Dec 15;104(12):2862-71
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors.
  • The authors conclude that these commonly used HDCT regimens provide no additional clinical benefit to conventional treatment in HGA, regardless of the amount of measurable residual tumor.
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Reference Values. Risk Assessment. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16315242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


71. Tabatabai G, Frank B, Möhle R, Weller M, Wick W: Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain; 2006 Sep;129(Pt 9):2426-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously we defined a pathway of transforming growth factor beta (TGF-beta) and stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-1alpha/CXCL12) dependent migration of adult haematopoietic stem and progenitor cells (HPC) towards glioma cells in vitro and their homing to experimental gliomas in vivo.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cell Hypoxia / physiology. Chemokines, CXC / physiology. Glioma / radiotherapy. Hematopoietic Stem Cells / physiology. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Transforming Growth Factor beta / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents, Alkylating / pharmacology. Brain / pathology. Brain / radiation effects. Cell Line, Tumor. Cell Movement / radiation effects. Chemokine CXCL12. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Gamma Rays. Humans. Immunohistochemistry / methods. Mice. Mice, Nude. Neoplasm Proteins / physiology. Promoter Regions, Genetic / genetics. Signal Transduction / genetics. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835250.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Neoplasm Proteins; 0 / Transforming Growth Factor beta; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


72. Cenzato M, Stefini R, Ambrosi C, Giovanelli M: Post-operative remnants of brainstem cavernomas: incidence, risk factors and management. Acta Neurochir (Wien); 2008 Sep;150(9):879-86; discussion 887

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative remnants of brainstem cavernomas: incidence, risk factors and management.
  • INTRODUCTION: The risk of leaving a remnant after surgery for a cavernous malformation in the brainstem is generally not stressed enough, even though such remnants appear to have a high risk of re-bleeding.
  • A retrospective analysis of 30 patients with brainstem cavernoma who underwent surgery is presented, focusing on incidence, risk factors and management of post-surgical residuals.
  • All patients had a brain MRI scan within 72 h after surgery to confirm that complete removal had been achieved.
  • CONCLUSION: Immediate post-operative brain MRI scans are therefore strongly recommended for their detection, especially in this group of patients, and if a residual is detected early re-intervention is less risky than the natural history.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Incidence. Magnetic Resonance Imaging. Middle Aged. Neoplasm, Residual / diagnosis. Neoplasm, Residual / epidemiology. Neoplasm, Residual / surgery. Postoperative Period. Reoperation. Risk Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754072.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


73. Ehtesham M, Sarangi A, Valadez JG, Chanthaphaychith S, Becher MW, Abel TW, Thompson RC, Cooper MK: Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene; 2007 Aug 23;26(39):5752-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the activity of this pathway in adult gliomas, and demonstrate that the Hh pathway is operational and activated within grade II and III gliomas, but not grade IV de novo glioblastoma multiforme.
  • These findings suggest a regulatory role for the Hh pathway in progenitor cells within grade II and III gliomas, and the potential clinical utility of monitoring and targeting this pathway in these primary brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Glioma / genetics. Hedgehog Proteins / genetics. Neoplastic Stem Cells / physiology. Signal Transduction
  • [MeSH-minor] Animals. Blotting, Western. Humans. Ligands. Mice. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptors, Cell Surface / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / physiology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353902.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS02133; United States / NINDS NIH HHS / NS / R01 NS051557
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Ligands; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


74. Ueoka DI, Nogueira J, Campos JC, Maranhão Filho P, Ferman S, Lima MA: Brainstem gliomas--retrospective analysis of 86 patients. J Neurol Sci; 2009 Jun 15;281(1-2):20-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem gliomas--retrospective analysis of 86 patients.
  • Brainstem gliomas constitute 10% of brain tumors in children and less than 2% in adults.
  • Since therapeutic options are limited and brainstem gliomas are associated with a high morbidity and mortality, we sought to analyze the prognostic factors associated with a better outcome.
  • We reviewed the records of 86 patients with brainstem gliomas treated between 1996 and 2006.
  • Of 86 patients with brainstem gliomas, 55.8% were females.
  • A short duration of symptoms, which may imply a more aggressive tumor, was associated with a worst prognosis in patients with brainstem gliomas.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Brain Stem / pathology. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345380.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Iagaru A, Masamed R, Singer PA, Conti PS: Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol; 2007 Mar-Apr;9(2):72-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography / methods. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rays. 2000 Apr-Jun;25(2):273-82 [11370545.001]
  • [Cites] J Endocrinol Invest. 1997 Oct;20(9):527-30 [9413806.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1671-6 [11702109.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Mar;5(2):139-48 [15810878.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):490-6 [10853802.001]
  • [Cites] Am J Med. 1994 Nov;97(5):418-28 [7977430.001]
  • [Cites] Eur J Nucl Med. 2001 Jan;28(1):64-71 [11202454.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):540-3 [14870781.001]
  • [Cites] Surgery. 1997 Dec;122(6):1049-60; discussion 1060-1 [9426419.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Eur J Nucl Med. 1996 Oct;23 (10 ):1367-71 [8781142.001]
  • [Cites] Thyroid. 1999 Aug;9(8):797-804 [10482373.001]
  • [Cites] Nucl Med Commun. 2004 May;25(5):439-43 [15100501.001]
  • [Cites] Nucl Med Commun. 1999 Apr;20(4):353-9 [10319355.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] J Nucl Med. 2002 Jan;43(1):66-71 [11801705.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73 [9578814.001]
  • [Cites] Nucl Med Biol. 1996 Aug;23 (6):717-35 [8940714.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):786-94 [15289241.001]
  • [Cites] Surgery. 1994 Dec;116(6):1017-23 [7985081.001]
  • [Cites] Acta Med Austriaca. 2003;30(1):22-5 [12558562.001]
  • (PMID = 17186139.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Notarianni C, Akin M, Fowler M, Nanda A: Brainstem astroblastoma: a case report and review of the literature. Surg Neurol; 2008 Feb;69(2):201-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem astroblastoma: a case report and review of the literature.
  • BACKGROUND: Astroblastoma is a rare glial tumor that occurs mainly in the cerebral hemispheres of young adults.
  • Our purpose in writing this article is to report one case of astroblastoma located within the medulla and review the literature on this infrequent tumor.
  • Light microscopy demonstrated a papillary neoplasm composed of mildly pleomorphic cells with indistinct cytoplasmic borders.
  • Occasional rosettes of tumor cells were seen around blood vessels.
  • The tumor exhibited thickened but not hyalinized blood vessel walls.
  • The tumor cells exhibited strong staining for EMA and vimentin throughout the tissue section.
  • Neurofilament, CAM 5.2, and CK immunostains were negative, except for rare positive staining of CK between cells and within rare tumor cells.
  • Ki-67 was positive in small numbers of tumor nuclei, with an overall reactivity of 7%.
  • By electron microscopy, the tumor nuclei had irregularly round to oval nuclei with moderate clumping of the chromatin, especially at the nuclear margins.
  • CONCLUSIONS: The combination of the radiologic and histopathologic characteristics of this tumor is necessary for making the diagnosis of astroblastoma.
  • This article serves to summarize these characteristics as well as to report of an unusual location for this mainly hemispheric tumor.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Astroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765957.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


82. Li DR, Ishikawa T, Zhao D, Michiue T, Quan L, Zhu BL, Maeda H: Unexpected sudden death due to intracranial chordoma: an autopsy case. Forensic Sci Int; 2010 Jul 15;200(1-3):e15-8
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an autopsy case of a sudden unexpected death due to clinically undiagnosed intracranial chordoma in the brainstem without haemorrhage.
  • The autopsy revealed two small gelatinous and semi-translucent greyish tumours on the ventral surface of the brainstem between the midbrain and pons.
  • The brain was markedly swollen, with enlarged lateral and third ventricles, but the aqueduct was compressed and narrowed.
  • The cause of death was diagnosed as acute obstructive hydrocephalus due to a ventral brainstem tumour.
  • The brainstem is one of the most vulnerable regions in the brain, and careful examination of this region is important for forensic pathologists.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Chordoma / pathology. Death, Sudden / etiology
  • [MeSH-minor] Adult. Brain / pathology. Forensic Pathology. Humans. Hydrocephalus / etiology. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20444561.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


83. Kozić D, Nagulić M, Samardzić M, Ostojić J, Rasulić L, Cvetković-Dozić D: Intrapontine malignant nerve sheath tumor: MRI and MRS features. Acta Neurol Belg; 2008 Jun;108(2):67-71
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapontine malignant nerve sheath tumor: MRI and MRS features.
  • The primary source of malignant intracerebral nerve sheath tumors is still unclear We report the imaging and MR spectroscopic findings in a 39-year-old man with a very rare brain stem tumor MR examination revealed the presence of intraaxial brain stem tumor with a partial exophytic growth.
  • On pathological examination, the neoplasm appeared to be an intrapontine nerve sheath tumor originating most likely from the intrapontine segment of one of the cranial nerve fibres.
  • The tumor showed exophytic growth, with consequent spread to adjacent subaracnoid space.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Nerve Sheath Neoplasms / pathology. Pons / pathology
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795600.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


84. Gerganov VM, Klinge PM, Nouri M, Stieglitz L, Samii M, Samii A: Prognostic clinical and radiological parameters for immediate facial nerve function following vestibular schwannoma surgery. Acta Neurochir (Wien); 2009 Jun;151(6):581-7; discussion 587
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / surgery. Dissection / adverse effects. Dissection / methods. Dissection / standards. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Invasiveness / pathology. Petrous Bone / anatomy & histology. Petrous Bone / pathology. Petrous Bone / surgery. Predictive Value of Tests. Prognosis. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337682.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


85. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg; 2009 Sep;36(3):446-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Emerging evidence suggests that specific sub-populations of cancer cells with stem cell characteristics within the bulk of tumours are implicated in the pathogenesis of heterogeneous malignant tumours.
  • The cells that drive tumour growth have been denoted cancer-initiating cells or cancer stem cells (hereafter CSCs).
  • CSCs have been isolated initially from leukaemias and subsequently from several solid tumours including brain, breast, prostate, colon and lung cancer.
  • (2) Hoechst 33342 dye exclusion test for the identification of a side-population characteristic for the presence of stem cells;.
  • (3) non-adherent culture condition able to form spheres with stem cell-like characteristics.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Glycoproteins / metabolism. Lung Neoplasms / pathology. Neoplastic Stem Cells / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cell Proliferation. Cell Transformation, Neoplastic / metabolism. Female. Flow Cytometry / methods. Humans. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Apr;37(4):988; author reply 988-9 [19945887.001]
  • (PMID = 19464919.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptides
  •  go-up   go-down


86. Zhang M, Segerer F, Ketonen L, Mahajan A, Wolff J: Prediction of tumour regrowth of pontine glioma using a two-term model. Anticancer Res; 2008 Mar-Apr;28(2A):741-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Glioma / pathology. Models, Biological
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507015.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Greece
  •  go-up   go-down


87. Yadav BS, Sharma SC, Singh R, Singh G, Kumar V: Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther; 2007 Oct-Dec;3(4):218-24
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On univariate analyses, factors affecting LRR were age < 40 years (0.019), tumor stage ( P = 0.001 ), grade ( P = 0.027 ), pathological nodal status ( P ), deep resection plane (0.041), ER/PR status ( P = 0.032 ) and postmastectomy radiation therapy (PMRT) ( P ).
  • Factors affecting distant metastases were age < 40 years (0.005), tumor stage ( P ), grade ( P = 0.0007 ), pathological nodal status ( P ), extra capsular extension (ECE) ( P = 0.002 ), hormonal therapy ( P ) and PMRT ( P ).
  • Factors affecting OS were tumor stage ( P ), grade ( P = 0.0001 ), pathological nodal status ( P ), ECE ( P = 0.002 ) ER/PR status ( P = 0.008 ), hormonal therapy ( P = 0.001 ) and PMRT ( P = 0.004 ).
  • On multivariate analysis, factors affecting LRR were age ( P = 0.001 ), tumor stage ( P = 0.021 ), deep resection plane (0.003), ECE ( P = 0.022 ) and PMRT ( P = 0.047 ).
  • Factors affecting OS were menopausal status ( P = 0.017 ), tumor stage ( P = 0.029 ), pathological nodal status ( P = 0.011 ) and PMRT ( P = 0.002 ).
  • Other factors of prognostic importance were menopausal status, tumor stage and pathological nodal status.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Mastectomy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Brain Stem Neoplasms / radiotherapy. Brain Stem Neoplasms / secondary. Brain Stem Neoplasms / surgery. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270397.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


88. Campos WK, Linhares MN: Sporadic intramedullary spinal cord hemangioblastoma in a newborn. Pediatr Neurosurg; 2010;46(5):385-9
Genetic Alliance. consumer health - Hemangioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spinal cord HB are usually diagnosed in adult patients and their incidence in early infancy is an extreme rarity.
  • MRI of the spine revealed an intramedullary tumor extending from level T6 to T12.
  • RESULTS: The tumor was excised completely, using standard microsurgical techniques via a posterior approach.
  • CONCLUSION: A review of the literature revealed that this neoplasm is composed of 3 major cell types: endothelial cells, pericytes and stromal cells.
  • Complete microsurgical removal is the treatment of choice for spinal cord HB because the tumor is benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389752.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


89. Gokce M: Analysis of isolated cranial nerve manifestations in patients with cancer. J Clin Neurosci; 2005 Nov;12(8):882-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They included meningeal carcinomatosis (10/16), brain stem metastases (3/16), primary brain astrocytomas (1/16), and metastases out of the central nervous system (2/16).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / secondary. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326269.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


90. Kawamata T, Kubo O, Hori T: Histological findings at the boundary of craniopharyngiomas. Brain Tumor Pathol; 2005;22(2):75-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a craniopharyngioma is grossly well circumscribed, microscopically the borders are frequently irregular and may be associated with gliosis in the adjacent brain tissue.
  • In type 1, a relatively thick capsule-like tissue was identified at the boundary between the craniopharyngioma and surrounding normal structure composed of tumor cells and inflammatory changes.
  • In type 3, the boundary had some interdigitation of the tumor in the surrounding gliotic layer adjacent to the craniopharyngioma.
  • In types 1 and 3, surgeons may fail to accomplish complete resection of the tumor.
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Stem / ultrastructure. Child. Child, Preschool. Female. Gliosis / etiology. Gliosis / pathology. Humans. Infant. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Visual Pathways / ultrastructure. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095108.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Bouetel V, Lescanne E, François P, Jan M, Morinière S, Robier A: [Evolution of facial nerve prognosis in vestibular schwannoma surgery by translabyrinthine approach]. Rev Laryngol Otol Rhinol (Bord); 2008;129(1):27-33
MedlinePlus Health Information. consumer health - Acoustic Neuroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Aged. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Nerve Diseases / diagnosis. Facial Nerve Diseases / physiopathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777766.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


92. Kawataki T, Sato E, Sato T, Kinouchi H: Anaplastic ganglioglioma with malignant features in both neuronal and glial components--case report. Neurol Med Chir (Tokyo); 2010;50(3):228-31
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was subtotally removed, followed by irradiation and chemotherapy.
  • Though these cells were weakly positive for synaptophysin and glial fibrillary acidic protein, the neural stem cell marker nestin was extremely expressed in both these cells.
  • Two months later, the tumor recurred with more pleomorphic appearance and higher cellularity with increased nestin expression level.
  • The expression of nestin may suggest that the origin or malignant transformation in anaplastic gangliogliomas is related to the undifferentiated neural stem cells.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Intermediate Filament Proteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Neuroglia / pathology. Neurons / pathology
  • [MeSH-minor] Adult. Anaplasia. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local. Nestin. Seizures / etiology. Seizures / pathology. Temporal Lobe / cytology. Temporal Lobe / metabolism. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • Genetic Alliance. consumer health - Anaplastic Ganglioglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339274.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


93. Laigle-Donadey F, Doz F, Delattre JY: Brainstem gliomas in children and adults. Curr Opin Oncol; 2008 Nov;20(6):662-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem gliomas in children and adults.
  • PURPOSE OF REVIEW: The purpose of this review is to determine if recent advances in diagnostic and treatment modalities result in improvement in the pattern of care of brainstem gliomas.
  • RECENT FINDINGS: New MRI techniques may contribute to differential diagnosis and aid neurosurgeons in removing resectable brainstem tumors.
  • However, biopsy remains indicated in many contrast enhancing brainstem masses in adults because of the great variety of differential diagnosis.
  • SUMMARY: Diffuse brainstem glioma is the most common subtype of brainstem tumor and remains a devastating malignancy in children.
  • Given the lack of efficacy of conventional drugs, a better understanding of the biology of this tumor is the key to more targeted therapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Stem / pathology. Glioma / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Child. Drug Delivery Systems. Humans. Magnetic Resonance Imaging / methods. Medical Oncology / methods. Neoplasm Metastasis. Neurofibromatosis 1 / drug therapy. Neurofibromatosis 1 / pathology. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841048.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 57
  •  go-up   go-down


94. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1990 to 1997, 312 patients<or=60 years with an elevated LDH were randomized to five cycles CHOEP+involved field (IF) radiotherapy or three cycles CHOEP followed by high-dose BCNU, etoposide, cytarabine and melphalan (BEAM) and autologous stem-cell transplantation (NHL-A study).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


95. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were: neuroblastoma (NB; n = 17), medulloblastoma (MB; 8), brain stem glioma (BSG; 8), extraosseous Ewing's sarcoma/peripheral neuroectodermal tumor (EOES; 4), Ewing's sarcoma (ES; 4), anaplastic astrocytoma (AA; 3), rhabdomyosarcoma (RMS; 2), ependymoma (EP; 2), cerebral primitive neuroectodermal tumor (cPNET; 2), hepatocarcinoma (HC; 1), and osteosarcoma (OS; 1).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


96. Newlin HE, Morris CG, Amdur RJ, Mendenhall WM: Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol; 2005 Aug;28(4):399-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this article is to report our experience with neurotropic melanoma, a rare malignancy that sometimes produces neurologic symptoms because of a direct extension of the primary tumor.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Peripheral Nervous System Neoplasms / radiotherapy. Peripheral Nervous System Neoplasms / surgery. Radiotherapy, Adjuvant. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062083.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Schild AM, Fricke J, Herkenrath P, Bolz H, Neugebauer A: [Neuro-ophthalmological and ophthalmological findings in Joubert syndrome]. Klin Monbl Augenheilkd; 2010 Oct;227(10):786-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adolescent. Amblyopia / diagnosis. Amblyopia / genetics. Antigens, Neoplasm / genetics. Blepharoptosis / diagnosis. Blepharoptosis / genetics. Brain Stem / abnormalities. Brain Stem / pathology. Cerebellum / abnormalities. Cerebellum / pathology. Child. Child, Preschool. Consanguinity. DNA Mutational Analysis. Electroretinography. Facial Paralysis / diagnosis. Facial Paralysis / genetics. Female. Fundus Oculi. Humans. Magnetic Resonance Imaging. Male. Membrane Proteins / genetics. Neoplasm Proteins / genetics. Nystagmus, Optokinetic / genetics. Ocular Motility Disorders / diagnosis. Ocular Motility Disorders / genetics. Refraction, Ocular. Retrospective Studies. Strabismus / diagnosis. Strabismus / genetics. Visual Acuity. Young Adult

  • Genetic Alliance. consumer health - Joubert Syndrome.
  • MedlinePlus Health Information. consumer health - Cerebellar Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20963681.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Cep290 protein, human; 0 / Membrane Proteins; 0 / NPHP1 protein, human; 0 / Neoplasm Proteins; Arima syndrome
  •  go-up   go-down


98. Majchrzak H, Krawczyk L, Majchrzak K, Bierzyńska-Macyszyn G: [Surgical treatment of brainstem gliomas and other tumors in adults]. Neurol Neurochir Pol; 2005 Jan-Feb;39(1):27-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of brainstem gliomas and other tumors in adults].
  • BACKGROUND AND PURPOSE: After the introduction of MR imaging to the diagnostics of brainstem tumors and after the introduction of microsurgical procedures to their treatment, the successful treatment, particularly of focal and exophytic forms of these tumors has begun all over the world.
  • The objective of this paper is to establish indications for surgical treatment of gliomas and other tumors of brainstem, to determine surgical approaches and to establish the outcome.
  • MATERIAL AND METHODS: Within the last 6 years, 12 patients with focal and exophytic tumors of the brainstem in adults were operated on.
  • CONCLUSIONS: Patients with focal and exophytic forms of the brainstem tumors in MR imaging are qualified for surgical treatment.
  • Immediate results of the treatment depend on the localization and size of the neoplasm.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Neurosurgical Procedures
  • [MeSH-minor] Adult. Brain Neoplasms / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Postoperative Complications / prevention & control. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735987.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


99. Yasui T, Komiyama M, Iwai Y, Yamanaka K, Matsusaka Y, Morikawa T, Ishiguro T: A brainstem cavernoma demonstrating a dramatic, spontaneous decrease in size during follow-up: case report and review of the literature. Surg Neurol; 2005 Feb;63(2):170-3; discussion 173

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A brainstem cavernoma demonstrating a dramatic, spontaneous decrease in size during follow-up: case report and review of the literature.
  • This report describes a large brainstem cavernoma showing a spontaneous, dramatic reduction in size after removal of only the biopsy specimen of the lesion.
  • She was in a bedridden state with severe brainstem dysfunction when she was transferred to a local hospital.
  • CONCLUSION: A dramatic, spontaneous decrease in size does occur even in the case of a large brainstem cavernoma showing hemorrhages.
  • Conservative therapy may be one of the treatment options for the symptomatic brainstem cavernoma.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / pathology. Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / pathology. Neoplasm Regression, Spontaneous / pathology
  • [MeSH-minor] Adult. Biopsy. Brain Stem / pathology. Female. Follow-Up Studies. Hematoma / surgery. Humans. Magnetic Resonance Imaging. Pons / pathology. Prognosis. Suction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680664.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


100. Prabhu K, Daniel RT, Mani S, Chacko AG: Dermoid tumor with diastematobulbia. Surg Neurol; 2009 Dec;72(6):717-21; discussion 721

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoid tumor with diastematobulbia.
  • Dermoid tumor with diastematobulbia is very rare.
  • CASE DESCRIPTION: We report a dermoid tumor in an adult female with an unusual location and morphology.
  • The anterior part of the lesion was situated in the prepontine cistern and encircling the anterior half of the brainstem.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Cerebral Ventricle Neoplasms / surgery. Cisterna Magna / surgery. Dermoid Cyst / surgery. Fourth Ventricle / surgery. Medulla Oblongata / surgery. Neoplasms, Multiple Primary / surgery. Pons / surgery
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neural Tube Defects / diagnosis. Neural Tube Defects / pathology. Neural Tube Defects / surgery. Neurologic Examination. Postoperative Complications / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19608253.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement